<SEC-DOCUMENT>0000950170-24-121089.txt : 20241105
<SEC-HEADER>0000950170-24-121089.hdr.sgml : 20241105
<ACCEPTANCE-DATETIME>20241105083135
ACCESSION NUMBER:		0000950170-24-121089
CONFORMED SUBMISSION TYPE:	8-K
PUBLIC DOCUMENT COUNT:		13
CONFORMED PERIOD OF REPORT:	20241105
ITEM INFORMATION:		Results of Operations and Financial Condition
ITEM INFORMATION:		Financial Statements and Exhibits
FILED AS OF DATE:		20241105
DATE AS OF CHANGE:		20241105

FILER:

	COMPANY DATA:	
		COMPANY CONFORMED NAME:			Inozyme Pharma, Inc.
		CENTRAL INDEX KEY:			0001693011
		STANDARD INDUSTRIAL CLASSIFICATION:	PHARMACEUTICAL PREPARATIONS [2834]
		ORGANIZATION NAME:           	03 Life Sciences
		IRS NUMBER:				475129768
		STATE OF INCORPORATION:			DE
		FISCAL YEAR END:			1231

	FILING VALUES:
		FORM TYPE:		8-K
		SEC ACT:		1934 Act
		SEC FILE NUMBER:	001-39397
		FILM NUMBER:		241425879

	BUSINESS ADDRESS:	
		STREET 1:		321 SUMMER STREET
		STREET 2:		SUITE 400
		CITY:			BOSTON
		STATE:			MA
		ZIP:			02210
		BUSINESS PHONE:		857-330-4340

	MAIL ADDRESS:	
		STREET 1:		321 SUMMER STREET
		STREET 2:		SUITE 400
		CITY:			BOSTON
		STATE:			MA
		ZIP:			02210

	FORMER COMPANY:	
		FORMER CONFORMED NAME:	Inozyme Pharma, LLC
		DATE OF NAME CHANGE:	20161222
</SEC-HEADER>
<DOCUMENT>
<TYPE>8-K
<SEQUENCE>1
<FILENAME>inzy-20241105.htm
<DESCRIPTION>8-K
<TEXT>
<XBRL>
<?xml version='1.0' encoding='ASCII'?>
<!-- DFIN New ActiveDisclosure (SM) Inline XBRL Document - http://www.dfinsolutions.com/ -->
<!-- Creation Date :2024-11-04T20:19:06.1314+00:00 -->
<!-- Copyright (c) 2024 Donnelley Financial Solutions, Inc. All Rights Reserved. -->
<html xmlns="http://www.w3.org/1999/xhtml" xmlns:xbrldi="http://xbrl.org/2006/xbrldi" xmlns:xbrldt="http://xbrl.org/2005/xbrldt" xmlns:xbrli="http://www.xbrl.org/2003/instance" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:ix="http://www.xbrl.org/2013/inlineXBRL" xmlns:nonNumeric="http://www.xbrl.org/dtr/type/non-numeric" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xmlns:dei="http://xbrl.sec.gov/dei/2024" xmlns:ixt-sec="http://www.sec.gov/inlineXBRL/transformation/2015-08-31" xmlns:ixt="http://www.xbrl.org/inlineXBRL/transformation/2022-02-16" xmlns:inzy="http://www.inozyme.com/20241105">
 <head>
  <title>8-K</title>
  <meta http-equiv="Content-Type" content="text/html"/>
 </head>
 <body style="margin: auto!important;padding: 8px;line-height: 1;">
  <div style="display:none;"><ix:header><ix:hidden><ix:nonNumeric id="F_865e8d41-72ea-46e1-8eef-4d682920afa6" name="dei:AmendmentFlag" contextRef="C_cb007e65-08e4-4ab7-b031-aea3e45b9ea2">false</ix:nonNumeric><ix:nonNumeric id="F_ccc48183-45c9-4d39-8c5c-822bf3834c4e" name="dei:EntityCentralIndexKey" contextRef="C_cb007e65-08e4-4ab7-b031-aea3e45b9ea2">0001693011</ix:nonNumeric></ix:hidden><ix:references><link:schemaRef xlink:type="simple" xlink:href="inzy-20241105.xsd"/></ix:references><ix:resources><xbrli:context id="C_cb007e65-08e4-4ab7-b031-aea3e45b9ea2"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001693011</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:startDate>2024-11-05</xbrli:startDate><xbrli:endDate>2024-11-05</xbrli:endDate></xbrli:period></xbrli:context></ix:resources></ix:header></div>
  <div style="z-index:-3;min-height:0.5in;position:relative;"></div>
  <p style="border-top:2.25pt double #000000;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p>
  <p style="font-size:10pt;margin-top:5.75pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:18pt;font-family:Times New Roman;min-width:fit-content;">UNITED STATES<br/>SECURITIES AND EXCHANGE COMMISSION<br/></span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">WASHINGTON, D.C. 20549</span></p>
  <p style="margin-left:40%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;border-bottom:0.75pt solid #000000;margin-right:40%;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p>
  <p style="font-size:10pt;margin-top:10pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:18pt;font-family:Times New Roman;min-width:fit-content;">FORM </span><span style="font-size:18pt;font-family:Times New Roman;"><ix:nonNumeric id="F_55e73f2b-21b3-4643-b03c-cbe849162b47" contextRef="C_cb007e65-08e4-4ab7-b031-aea3e45b9ea2" name="dei:DocumentType"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:18pt;font-family:Times New Roman;min-width:fit-content;">8-K</span></ix:nonNumeric></span></p>
  <p style="margin-left:40%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;border-bottom:0.75pt solid #000000;margin-right:40%;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p>
  <p style="font-size:10pt;margin-top:9pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">CURRENT REPORT</span></p>
  <p style="font-size:10pt;margin-top:9pt;font-family:Times New Roman;margin-bottom:6pt;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934</span></p>
  <table style="border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;">
   <tr style="visibility:collapse;">
    <td style="width:100%;box-sizing:content-box;"/>
   </tr>
   <tr style="height:10pt;white-space:pre-wrap;word-break:break-word;text-align:left;">
    <td style="padding-top:0.01in;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.02986111111111111in;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">Date of Report (Date of earliest event reported): </span><span><ix:nonNumeric id="F_8a7afb70-fb88-4df2-92ba-a72c1389807e" contextRef="C_cb007e65-08e4-4ab7-b031-aea3e45b9ea2" name="dei:DocumentPeriodEndDate" format="ixt:date-monthname-day-year-en"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">November 05, 2024</span></ix:nonNumeric></span></p></td>
   </tr>
  </table>
  <p style="margin-left:40%;font-size:10pt;margin-top:5pt;font-family:Times New Roman;margin-bottom:0;border-bottom:0.75pt solid #000000;margin-right:40%;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p>
  <p style="font-size:10pt;margin-top:5pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="font-size:24pt;font-family:Times New Roman;"><ix:nonNumeric id="F_da22e601-1717-476b-8715-497f54f6315d" contextRef="C_cb007e65-08e4-4ab7-b031-aea3e45b9ea2" name="dei:EntityRegistrantName"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:24pt;font-family:Times New Roman;min-width:fit-content;">INOZYME PHARMA, INC.</span></ix:nonNumeric></span></p>
  <p style="font-size:10pt;margin-top:3pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:7.5pt;font-family:Times New Roman;min-width:fit-content;">(Exact name of Registrant as Specified in Its Charter)</span></p>
  <p style="margin-left:40%;font-size:10pt;margin-top:9pt;font-family:Times New Roman;margin-bottom:0;border-bottom:0.75pt solid #000000;margin-right:40%;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p>
  <table style="border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;">
   <tr style="visibility:collapse;">
    <td style="width:20%;box-sizing:content-box;"/>
    <td style="width:1%;box-sizing:content-box;"/>
    <td style="width:20%;box-sizing:content-box;"/>
    <td style="width:18%;box-sizing:content-box;"/>
    <td style="width:41%;box-sizing:content-box;"/>
   </tr>
   <tr style="height:10pt;white-space:pre-wrap;word-break:break-word;text-align:left;">
    <td colspan="3" style="padding-top:0.01in;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span><ix:nonNumeric id="F_414724be-d0b8-4cea-8d9e-591d416b05b3" contextRef="C_cb007e65-08e4-4ab7-b031-aea3e45b9ea2" name="dei:EntityIncorporationStateCountryCode" format="ixt-sec:stateprovnameen"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">Delaware</span></ix:nonNumeric></span></p></td>
    <td style="padding-top:0.01in;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span><ix:nonNumeric id="F_e9ae4fbc-e055-46c3-8ad0-598339471a4d" contextRef="C_cb007e65-08e4-4ab7-b031-aea3e45b9ea2" name="dei:EntityFileNumber"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">001-39397</span></ix:nonNumeric></span></p></td>
    <td style="padding-top:0.01in;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span><ix:nonNumeric id="F_49321344-14cd-421e-a3a6-1652ccda4868" contextRef="C_cb007e65-08e4-4ab7-b031-aea3e45b9ea2" name="dei:EntityTaxIdentificationNumber"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">38-4024528</span></ix:nonNumeric></span></p></td>
   </tr>
   <tr style="height:7pt;white-space:pre-wrap;word-break:break-word;text-align:left;">
    <td colspan="3" style="padding-top:0.01in;vertical-align:top;"><p style="font-size:7.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">(State or Other Jurisdiction<br/>of Incorporation)</span></p></td>
    <td style="padding-top:0.01in;vertical-align:top;"><p style="font-size:7.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">(Commission File Number)</span></p></td>
    <td style="padding-top:0.01in;vertical-align:top;"><p style="font-size:7.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">(IRS Employer<br/>Identification No.)</span></p></td>
   </tr>
   <tr style="white-space:pre-wrap;word-break:break-word;text-align:left;">
    <td style="padding-top:0.01in;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10pt;white-space:pre-wrap;word-break:break-word;text-align:left;">
    <td colspan="3" style="padding-top:0.01in;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span><ix:nonNumeric id="F_9cea67d2-38bf-4f01-a747-00866000b644" contextRef="C_cb007e65-08e4-4ab7-b031-aea3e45b9ea2" name="dei:EntityAddressAddressLine1"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">321 Summer Street</span></ix:nonNumeric></span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span><ix:nonNumeric id="F_8277d43d-6c52-4a8c-b48c-457102e7cdbd" contextRef="C_cb007e65-08e4-4ab7-b031-aea3e45b9ea2" name="dei:EntityAddressAddressLine2"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">Suite 400</span></ix:nonNumeric></span></p></td>
    <td colspan="2" style="padding-top:0.01in;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10pt;white-space:pre-wrap;word-break:break-word;">
    <td colspan="3" style="padding-top:0.01in;vertical-align:top;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span><ix:nonNumeric id="F_c21e0941-2364-41f6-a334-e12738b68dce" contextRef="C_cb007e65-08e4-4ab7-b031-aea3e45b9ea2" name="dei:EntityAddressCityOrTown"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">Boston</span></ix:nonNumeric></span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">, </span><span><ix:nonNumeric id="F_319bb30d-0aa3-4b6c-a173-55ced94bb37c" contextRef="C_cb007e65-08e4-4ab7-b031-aea3e45b9ea2" name="dei:EntityAddressStateOrProvince" format="ixt-sec:stateprovnameen"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">Massachusetts</span></ix:nonNumeric></span></p></td>
    <td style="padding-top:0.01in;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span><ix:nonNumeric id="F_fbc21aff-dcd8-47bf-b509-218a68ef9c91" contextRef="C_cb007e65-08e4-4ab7-b031-aea3e45b9ea2" name="dei:EntityAddressPostalZipCode"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">02210</span></ix:nonNumeric></span></p></td>
   </tr>
   <tr style="height:7pt;white-space:pre-wrap;word-break:break-word;text-align:left;">
    <td colspan="3" style="padding-top:0.01in;vertical-align:top;"><p style="font-size:7.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">(Address of Principal Executive Offices)</span></p></td>
    <td style="padding-top:0.01in;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;vertical-align:top;"><p style="font-size:7.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">(Zip Code)</span></p></td>
   </tr>
  </table>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p>
  <table style="border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;">
   <tr style="visibility:collapse;">
    <td style="width:100%;box-sizing:content-box;"/>
   </tr>
   <tr style="height:10pt;white-space:pre-wrap;word-break:break-word;text-align:left;">
    <td style="padding-top:0.125in;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.02986111111111111in;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">Registrant&#8217;s Telephone Number, Including Area Code: (</span><span><ix:nonNumeric id="F_c0a0feed-9e1c-4cad-aaa3-c8471c78b11f" contextRef="C_cb007e65-08e4-4ab7-b031-aea3e45b9ea2" name="dei:CityAreaCode"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">857</span></ix:nonNumeric></span><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">) </span><span><ix:nonNumeric id="F_d91c658c-5956-4bee-9078-15512b705d25" contextRef="C_cb007e65-08e4-4ab7-b031-aea3e45b9ea2" name="dei:LocalPhoneNumber"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">330-4340</span></ix:nonNumeric></span></p></td>
   </tr>
  </table>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p>
  <table style="border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;">
   <tr style="visibility:collapse;">
    <td style="width:100%;box-sizing:content-box;"/>
   </tr>
   <tr style="white-space:pre-wrap;word-break:break-word;text-align:left;">
    <td style="padding-top:0.125in;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
   </tr>
  </table>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:7.5pt;font-family:Times New Roman;min-width:fit-content;">(Former Name or Former Address, if Changed Since Last Report)</span></p>
  <p style="margin-left:40%;font-size:10pt;margin-top:9.35pt;font-family:Times New Roman;margin-bottom:0;border-bottom:0.75pt solid #000000;margin-right:40%;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p>
  <p style="font-size:10pt;margin-top:9.35pt;font-family:Times New Roman;margin-bottom:6pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <div style="text-indent:-24.5pt;padding-left:24.5pt;margin-top:9pt;margin-bottom:0;text-align:left;"><span style="margin-right:1em;margin-right:1em;"><span style="font-size:10pt;font-family:Times New Roman;"><ix:nonNumeric id="F_e29dfa28-2627-44b9-a1a3-d9fa23f8c000" contextRef="C_cb007e65-08e4-4ab7-b031-aea3e45b9ea2" name="dei:WrittenCommunications" format="ixt-sec:boolballotbox"><span style="font-size:10pt;font-family:Times New Roman;">&#9744;</span></ix:nonNumeric></span></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)</span></div>
  <div style="text-indent:-24.5pt;padding-left:24.5pt;margin-top:6pt;margin-bottom:0;text-align:left;"><span style="margin-right:1em;margin-right:1em;"><span style="font-size:10pt;font-family:Times New Roman;"><ix:nonNumeric id="F_5f98f070-2ac6-4ac5-8cb9-8b3cf1fc6215" contextRef="C_cb007e65-08e4-4ab7-b031-aea3e45b9ea2" name="dei:SolicitingMaterial" format="ixt-sec:boolballotbox"><span style="font-size:10pt;font-family:Times New Roman;">&#9744;</span></ix:nonNumeric></span></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)</span></div>
  <div style="text-indent:-24.5pt;padding-left:24.5pt;margin-top:6pt;margin-bottom:0;text-align:left;"><span style="margin-right:1em;margin-right:1em;"><span style="font-size:10pt;font-family:Times New Roman;"><ix:nonNumeric id="F_809c86ea-357b-4b6b-89db-6df43a479c5a" contextRef="C_cb007e65-08e4-4ab7-b031-aea3e45b9ea2" name="dei:PreCommencementTenderOffer" format="ixt-sec:boolballotbox"><span style="font-size:10pt;font-family:Times New Roman;">&#9744;</span></ix:nonNumeric></span></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))</span></div>
  <div style="text-indent:-24.5pt;padding-left:24.5pt;margin-top:6pt;margin-bottom:0;text-align:left;"><span style="margin-right:1em;margin-right:1em;"><span style="font-size:10pt;font-family:Times New Roman;"><ix:nonNumeric id="F_5e62b329-d34e-4f3f-bac9-668dc8b032eb" contextRef="C_cb007e65-08e4-4ab7-b031-aea3e45b9ea2" name="dei:PreCommencementIssuerTenderOffer" format="ixt-sec:boolballotbox"><span style="font-size:10pt;font-family:Times New Roman;">&#9744;</span></ix:nonNumeric></span></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))</span></div>
  <p style="font-size:10pt;margin-top:9pt;font-family:Times New Roman;margin-bottom:9pt;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Securities registered pursuant to Section 12(b) of the Act:</span></p>
  <table style="border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;">
   <tr style="visibility:collapse;">
    <td style="width:38%;box-sizing:content-box;"/>
    <td style="width:1%;box-sizing:content-box;"/>
    <td style="width:15%;box-sizing:content-box;"/>
    <td style="width:1%;box-sizing:content-box;"/>
    <td style="width:45%;box-sizing:content-box;"/>
   </tr>
   <tr style="height:10pt;white-space:pre-wrap;word-break:break-word;">
    <td style="padding-top:0.01in;vertical-align:top;border-bottom:0.25pt solid;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;"><br/>Title of each class</span></p></td>
    <td style="padding-top:0.01in;vertical-align:top;border-bottom:0.25pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;vertical-align:top;border-bottom:0.25pt solid;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">Trading<br/>Symbol(s)</span></p></td>
    <td style="padding-top:0.01in;vertical-align:top;border-bottom:0.25pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;vertical-align:top;border-bottom:0.25pt solid;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;"><br/>Name of each exchange on which registered</span></p></td>
   </tr>
   <tr style="height:10pt;white-space:pre-wrap;word-break:break-word;">
    <td style="padding-top:0.01in;vertical-align:top;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span><ix:nonNumeric id="F_463be621-f6d6-46e0-9fdc-25c936b5eb39" contextRef="C_cb007e65-08e4-4ab7-b031-aea3e45b9ea2" name="dei:Security12bTitle"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Common stock, par value $0.0001 per share</span></ix:nonNumeric></span></p></td>
    <td style="padding-top:0.01in;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;vertical-align:top;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span><ix:nonNumeric id="F_9a27c23e-6005-44a8-b3f4-9ae68ea63972" contextRef="C_cb007e65-08e4-4ab7-b031-aea3e45b9ea2" name="dei:TradingSymbol"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">INZY</span></ix:nonNumeric></span></p></td>
    <td style="padding-top:0.01in;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;vertical-align:top;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span><ix:nonNumeric id="F_92c4ae50-6c4c-418d-8fd6-ca2930f45beb" contextRef="C_cb007e65-08e4-4ab7-b031-aea3e45b9ea2" name="dei:SecurityExchangeName" format="ixt-sec:exchnameen"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Nasdaq Global Select Market</span></ix:nonNumeric></span></p></td>
   </tr>
  </table>
  <p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (&#167;&#8239;230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (&#167;&#8239;240.12b-2 of this chapter).</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:9pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Emerging growth company </span><span style="font-size:10pt;"><ix:nonNumeric id="F_df343546-0651-450b-8eaa-94bbb8550340" contextRef="C_cb007e65-08e4-4ab7-b031-aea3e45b9ea2" name="dei:EntityEmergingGrowthCompany" format="ixt-sec:boolballotbox"><span style="font-size:10pt;font-family:Times New Roman;">&#9746;</span></ix:nonNumeric></span></p>
  <p style="font-size:10pt;margin-top:9pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. </span><span style="font-size:10pt;"><ix:nonNumeric id="F_0a053384-0ce8-41d2-becb-ec9a41251fd0" contextRef="C_cb007e65-08e4-4ab7-b031-aea3e45b9ea2" name="dei:EntityExTransitionPeriod" format="ixt-sec:boolballotbox"><span style="font-size:10pt;font-family:Times New Roman;">&#9744;</span></ix:nonNumeric></span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;border-bottom:2.25pt double #000000;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p>
  <div class="page-node-content"><div style="z-index:-3;flex-direction:column;display:flex;min-height:0.5in;justify-content:flex-end;position:relative;"></div></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;page-break-after:always;"/>
  <div style="z-index:-3;min-height:0.5in;position:relative;"></div>
  <p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:6pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Item 2.02 Results of Operations and Financial Condition.</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">On November 5, 2024, Inozyme Pharma, Inc. (the &#8220;Company&#8221;) announced its financial results for the quarter ended September 30, 2024. The full text of the press release issued in connection with the announcement is being furnished as Exhibit 99.1 to this Current Report on Form 8-K and is incorporated herein by reference.</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">  </span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">The information in this Item 2.02, including Exhibit 99.1 attached hereto, shall not be deemed &#8220;filed&#8221; for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the &#8220;Exchange Act&#8221;), or otherwise subject to the liabilities of that section, nor shall it be deemed incorporated by reference in any filing made by the Company under the Securities Act of 1933, as amended, or the Exchange Act, except as expressly set forth by specific reference in such a filing.</span></p>
  <p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:6pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Item 9.01 Financial Statements and Exhibits.</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">(d) Exhibits:</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">The following exhibit is furnished herewith:</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p>
  <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;">
   <tr style="visibility:collapse;">
    <td style="width:7.041%;box-sizing:content-box;"/>
    <td style="width:1.98%;box-sizing:content-box;"/>
    <td style="width:90.978%;box-sizing:content-box;"/>
   </tr>
   <tr style="height:10pt;white-space:pre-wrap;word-break:break-word;">
    <td style="padding-top:0.01in;vertical-align:top;border-bottom:0.75pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Exhibit</span></p></td>
    <td style="padding-top:0.01in;vertical-align:top;border-bottom:0.75pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"> </span></p></td>
    <td style="padding-top:0.01in;vertical-align:top;border-bottom:0.75pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Description</span></p></td>
   </tr>
   <tr style="height:10pt;white-space:pre-wrap;word-break:break-word;">
    <td style="padding-top:0.01in;vertical-align:top;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"> </span></p></td>
    <td style="padding-top:0.01in;vertical-align:top;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"> </span></p></td>
    <td style="padding-top:0.01in;vertical-align:top;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"> </span></p></td>
   </tr>
   <tr style="height:10pt;white-space:pre-wrap;word-break:break-word;">
    <td style="padding-top:0.01in;vertical-align:top;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">99.1</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">104</span></p></td>
    <td style="padding-top:0.01in;vertical-align:top;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"> </span></p></td>
    <td style="padding-top:0.01in;vertical-align:top;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><a href="inzy-ex99_1.htm"><span style="color:#0000ff;white-space:pre-wrap;text-decoration:underline;min-width:fit-content;">Press Release issued by the Company on November 5, 2024</span></a></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Cover Page Interactive Data File (embedded within the Inline XBRL document)</span></p></td>
   </tr>
  </table>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p>
  <div class="page-node-content"><div style="z-index:-3;flex-direction:column;display:flex;min-height:0.5in;justify-content:flex-end;position:relative;"></div></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;page-break-after:always;"/>
  <div style="z-index:-3;min-height:0.5in;position:relative;"></div>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:9.35pt;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">SIGNATURES</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:9.35pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned thereunto duly authorized.</span></p>
  <table style="border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;">
   <tr style="visibility:collapse;">
    <td style="width:6%;box-sizing:content-box;"/>
    <td style="width:44%;box-sizing:content-box;"/>
    <td style="width:4%;box-sizing:content-box;"/>
    <td style="width:46%;box-sizing:content-box;"/>
   </tr>
   <tr style="height:10pt;white-space:pre-wrap;word-break:break-word;">
    <td style="padding-top:0.01in;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;vertical-align:top;"><p style="font-size:10pt;margin-top:4.3pt;font-family:Times New Roman;margin-bottom:4.3pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">INOZYME PHARMA, INC.</span></p></td>
   </tr>
   <tr style="white-space:pre-wrap;word-break:break-word;">
    <td style="padding-top:0.01in;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10pt;white-space:pre-wrap;word-break:break-word;">
    <td style="padding-top:0.01in;vertical-align:top;"><p style="font-size:10pt;margin-top:4.3pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Date:</span></p></td>
    <td style="padding-top:0.01in;vertical-align:top;"><p style="font-size:10pt;margin-top:4.3pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">November 5, 2024</span></p></td>
    <td style="padding-top:0.01in;vertical-align:top;"><p style="font-size:10pt;margin-top:4.3pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">By:</span><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"> </span></p></td>
    <td style="padding-top:0.01in;vertical-align:top;border-bottom:0.25pt solid;"><p style="font-size:10pt;margin-top:4.3pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">/s/ Douglas A. Treco</span></p></td>
   </tr>
   <tr style="height:10pt;white-space:pre-wrap;word-break:break-word;">
    <td style="padding-top:0.01in;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;vertical-align:top;"><p style="font-size:10pt;margin-top:0.7pt;font-family:Times New Roman;margin-bottom:9.35pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Name: Douglas A. Treco<br/>Title: Chief Executive Officer</span></p></td>
   </tr>
  </table>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p>
  <div class="page-node-content"><div style="z-index:-3;flex-direction:column;display:flex;min-height:0.5in;justify-content:flex-end;position:relative;"></div></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;page-break-after:always;"/>
 </body>
</html>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-99.1
<SEQUENCE>2
<FILENAME>inzy-ex99_1.htm
<DESCRIPTION>EX-99.1
<TEXT>
<html>
 <head>
  <title>EX-99.1</title>
 </head>
 <body style="margin: auto!important;padding: 8px;line-height: 1;">
  <div style="padding-top:0.5in;z-index:-3;min-height:1in;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><img src="img4202433_0.jpg" alt="img4202433_0.jpg" style="width:180px;height:90px;"></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:'Aptos',sans-serif;min-width:fit-content;">Exhibit 99.1</font></p></div>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:12pt;font-family:'Calibri',sans-serif;min-width:fit-content;">Inozyme Pharma Reports Third Quarter 2024 Financial Results and Provides Business Highlights</font></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:12pt;font-family:'Calibri',sans-serif;min-width:fit-content;">&#160;</font></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:'Calibri',sans-serif;font-style:italic;min-width:fit-content;">- Interim data from ENERGY 1, a Phase 1b trial of INZ-701 in infants with ENPP1 Deficiency, on track for fourth quarter of 2024 &#x2013;</font></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><font style="white-space:pre-wrap;font-size:12pt;font-family:'Calibri',sans-serif;min-width:fit-content;">&#160;</font></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:'Calibri',sans-serif;font-style:italic;min-width:fit-content;">- Topline data from ENERGY 3, a pivotal trial of INZ-701 in pediatric patients with ENPP1 Deficiency, expected in early 2026 -</font></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><font style="white-space:pre-wrap;font-size:12pt;font-family:'Calibri',sans-serif;min-width:fit-content;">&#160;</font></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:'Calibri',sans-serif;font-style:italic;min-width:fit-content;">- Company plans to initiate registrational trials in calciphylaxis and ABCC6 Deficiency in 2025 subject to regulatory alignment and sufficient funding -</font></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:12pt;font-family:'Calibri',sans-serif;min-width:fit-content;">&#160;</font></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:'Calibri',sans-serif;font-style:italic;min-width:fit-content;">- Cash, cash equivalents, and short-term investments as of September 30, 2024, expected to fund operations into the fourth quarter of 2025 &#x2013;</font></p>
  <p style="margin-left:10%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:12pt;font-family:'Calibri',sans-serif;min-width:fit-content;">&#160;</font></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:12pt;font-family:'Calibri',sans-serif;min-width:fit-content;">BOSTON, November 5, 2024</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:'Calibri',sans-serif;min-width:fit-content;"> (GLOBE NEWSWIRE) -- </font><font><font style="white-space:pre-wrap;font-weight:bold;font-size:12pt;font-family:'Calibri',sans-serif;min-width:fit-content;">Inozyme Pharma, Inc.</font></font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:'Calibri',sans-serif;min-width:fit-content;"> (Nasdaq: INZY) (&#x201c;the Company&#x201d; or &#x201c;Inozyme&#x201d;), a clinical-stage biopharmaceutical company developing innovative therapeutics for rare diseases that affect bone health and blood vessel function, today reported financial results for the third quarter ended September 30, 2024, and provided business highlights.</font></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:12pt;font-family:'Calibri',sans-serif;min-width:fit-content;">&#160;</font></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:'Calibri',sans-serif;min-width:fit-content;">&#x201c;As we close in on the end of a highly productive year, our focus remains firmly on advancing INZ-701 across each of our clinical programs,&#x201d; said Douglas A. Treco, Ph.D., CEO and Chairman of Inozyme Pharma. &#x201c;The recent presentation of promising interim data from our Phase 1 data from our calciphylaxis program highlights our progress, and we remain on track to report interim data from our Phase 1b ENERGY 1 trial in ENPP1 Deficiency by year-end. With a growing body of clinical evidence supporting the potential for INZ-701 to serve as a meaningful therapy across multiple indications of high unmet need, we are committed to our mission to bring novel treatment options to patients facing rare diseases affecting bone health and blood vessel function.&#x201d;</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:'Calibri',sans-serif;min-width:fit-content;"> </font></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:12pt;font-family:'Calibri',sans-serif;min-width:fit-content;">&#160;</font></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:12pt;font-family:'Calibri',sans-serif;min-width:fit-content;">Recent Highlights</font></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:12pt;font-family:'Calibri',sans-serif;min-width:fit-content;">&#160;</font></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:'Calibri',sans-serif;font-style:italic;min-width:fit-content;">Pipeline</font></p>
  <div class="item-list-element-wrapper" style="margin-left:3.333%;display:flex;margin-top:0;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.333%;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:3.447919145106397%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#x2022;</font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:12pt;font-family:'Calibri',sans-serif;min-width:fit-content;">Presentations at American Society for Bone and Mineral Research (ASBMR) 2024 Annual Meeting. </font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:'Calibri',sans-serif;min-width:fit-content;">In September 2024, the Company </font><font><font style="white-space:pre-wrap;font-size:12pt;font-family:'Calibri',sans-serif;min-width:fit-content;">presented new data</font></font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:'Calibri',sans-serif;min-width:fit-content;"> at ASBMR 2024 in Toronto, Canada, demonstrating the progression and impact of ENPP1 Deficiency and ABCC6 Deficiency in children. These findings underscored the urgent need for innovative therapies to address the severe cardiovascular and musculoskeletal complications associated with these conditions. In addition, the Company and GACI Global highlighted the launch of the PROPEL Registry designed to further understanding of the burden of </font></div></div>
  <div class="page-node-content"><div style="z-index:-3;flex-direction:column;display:flex;min-height:1in;justify-content:flex-end;position:relative;"></div></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;page-break-after:always;">
  <div style="padding-top:0.5in;z-index:-3;min-height:1in;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><img src="img4202433_0.jpg" alt="img4202433_0.jpg" style="width:180px;height:90px;"></p></div>
  <div class="item-list-element-wrapper" style="margin-left:3.333%;display:flex;margin-top:0;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.333%;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:3.447919145106397%;visibility:hidden;word-break:keep-all;display:inline-flex;justify-content:flex-start;"></font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:'Calibri',sans-serif;min-width:fit-content;">illness and progressive nature of ENPP1 Deficiency and early-onset ABCC6 Deficiency (</font><font><font style="white-space:pre-wrap;font-size:12pt;font-family:'Calibri',sans-serif;min-width:fit-content;">NCT06302439</font></font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:'Calibri',sans-serif;min-width:fit-content;">).</font></div></div>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:12pt;font-family:'Calibri',sans-serif;min-width:fit-content;">&#160;</font></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:'Calibri',sans-serif;font-style:italic;min-width:fit-content;">ENPP1 Deficiency</font></p>
  <div class="item-list-element-wrapper" style="margin-left:3.333%;display:flex;margin-top:0;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.333%;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:3.447919145106397%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#x2022;</font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:12pt;font-family:'Calibri',sans-serif;min-width:fit-content;">ENPP1 Deficiency Review Series Publication</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:'Calibri',sans-serif;min-width:fit-content;">. In September 2024, a series of comprehensive review articles on ENPP1 Deficiency was published in the French journal of pediatrics, </font><font><font style="white-space:pre-wrap;font-size:12pt;font-family:'Calibri',sans-serif;font-style:italic;min-width:fit-content;">Archives de P&eacute;diatrie</font></font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:'Calibri',sans-serif;font-style:italic;min-width:fit-content;">. </font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:'Calibri',sans-serif;min-width:fit-content;">Authored by expert clinicians and researchers in bone health, the articles collectively highlight the complexities of ENPP1 Deficiency, underscoring both established and emerging insights into the disease&#x2019;s presentation and management.</font></div></div>
  <p style="margin-left:6.667%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:12pt;font-family:'Calibri',sans-serif;min-width:fit-content;">&#160;</font></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:'Calibri',sans-serif;font-style:italic;min-width:fit-content;">Calciphylaxis</font></p>
  <div class="item-list-element-wrapper" style="margin-left:3.333%;display:flex;margin-top:0;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.333%;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:3.447919145106397%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#x2022;</font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:12pt;font-family:'Calibri',sans-serif;min-width:fit-content;">Phase 1 Trial of INZ-701 in Patients with End-Stage Kidney Disease (ESKD) Undergoing Hemodialysis.</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:'Calibri',sans-serif;min-width:fit-content;"> In October 2024, the Company </font><font><font style="white-space:pre-wrap;font-size:12pt;font-family:'Calibri',sans-serif;min-width:fit-content;">announced</font></font><font style="color:#0000ff;white-space:pre-wrap;text-decoration:underline;font-size:12pt;font-family:'Calibri',sans-serif;min-width:fit-content;"> </font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:'Calibri',sans-serif;min-width:fit-content;">positive interim data demonstrating INZ-701 was well-tolerated and significantly increased plasma pyrophosphate (PPi) levels in patients with ESKD on dialysis. Low PPi levels are linked to the development of calciphylaxis, a rare and life-threatening complication of ESKD, as well as the associated morbidity and mortality. Data were featured at the American Society of Nephrology&#x2019;s </font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:'Calibri',sans-serif;font-style:italic;min-width:fit-content;">Kidney Week 2024</font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:12pt;font-family:'Calibri',sans-serif;min-width:fit-content;"> </font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:'Calibri',sans-serif;min-width:fit-content;">in</font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:12pt;font-family:'Calibri',sans-serif;min-width:fit-content;"> </font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:'Calibri',sans-serif;min-width:fit-content;">San Diego, CA. Subject to regulatory review and sufficient funding, the Company plans to initiate a registrational study in calciphylaxis in 2025.</font></div></div>
  <p style="margin-left:6.667%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:12pt;font-family:'Calibri',sans-serif;min-width:fit-content;">&#160;</font></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:'Calibri',sans-serif;font-style:italic;min-width:fit-content;">Corporate</font></p>
  <div class="item-list-element-wrapper" style="margin-left:3.333%;display:flex;margin-top:0;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.333%;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:3.447919145106397%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#x2022;</font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:12pt;font-family:'Calibri',sans-serif;min-width:fit-content;">Board of Directors Appointment.</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:'Calibri',sans-serif;min-width:fit-content;"> In October 2024, the Company </font><font><font style="white-space:pre-wrap;font-size:12pt;font-family:'Calibri',sans-serif;min-width:fit-content;">announced</font></font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:'Calibri',sans-serif;min-width:fit-content;"> the appointment of Erik Harris to its Board of Directors. Mr. Harris, who currently serves as Chief Commercial Officer and Executive Vice President at Ultragenyx Pharmaceutical Inc., brings to the Company over 20 years of commercial expertise within the biopharmaceutical industry.</font></div></div>
  <p style="margin-left:6.667%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:12pt;font-family:'Calibri',sans-serif;min-width:fit-content;">&#160;</font></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:12pt;font-family:'Calibri',sans-serif;min-width:fit-content;">Anticipated Milestones</font></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:12pt;font-family:'Calibri',sans-serif;min-width:fit-content;">&#160;</font></p>
  <div class="item-list-element-wrapper" style="margin-left:3.333%;display:flex;margin-top:0;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.333%;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:3.447919145106397%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#x2022;</font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:12pt;font-family:'Calibri',sans-serif;min-width:fit-content;">ENPP1 Deficiency</font></div></div>
  <div class="item-list-element-wrapper" style="margin-left:10%;display:flex;margin-top:0;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.333%;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:3.7033333333333336%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">o</font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:'Calibri',sans-serif;min-width:fit-content;">Complete enrollment of ENERGY 3 pivotal trial in pediatric patients by the end of 2024</font></div></div>
  <div class="item-list-element-wrapper" style="margin-left:10%;display:flex;margin-top:0;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.333%;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:3.7033333333333336%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">o</font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:'Calibri',sans-serif;min-width:fit-content;">Initiation of the ENERGY 2 pivotal trial in infants with ENPP1 Deficiency outside the United States in the fourth quarter of 2024</font></div></div>
  <div class="item-list-element-wrapper" style="margin-left:10%;display:flex;margin-top:0;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.333%;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:3.7033333333333336%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">o</font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:'Calibri',sans-serif;min-width:fit-content;">Release interim data from the ENERGY 1 Phase 1b trial in infants in the fourth quarter of 2024</font></div></div>
  <div class="item-list-element-wrapper" style="margin-left:10%;display:flex;margin-top:0;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.333%;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:3.7033333333333336%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">o</font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:'Calibri',sans-serif;min-width:fit-content;">Release topline data from the ENERGY 3 pivotal trial in pediatric patients in early 2026</font></div></div>
  <p style="margin-left:16.667%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</font></p>
  <div class="page-node-content"><div style="z-index:-3;flex-direction:column;display:flex;min-height:1in;justify-content:flex-end;position:relative;"></div></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;page-break-after:always;">
  <div style="padding-top:0.5in;z-index:-3;min-height:1in;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><img src="img4202433_0.jpg" alt="img4202433_0.jpg" style="width:180px;height:90px;"></p></div>
  <div class="item-list-element-wrapper" style="margin-left:3.333%;display:flex;margin-top:0;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.333%;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:3.447919145106397%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#x2022;</font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:12pt;font-family:'Calibri',sans-serif;min-width:fit-content;">ABCC6 Deficiency</font></div></div>
  <div class="item-list-element-wrapper" style="margin-left:10%;display:flex;margin-top:0;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.333%;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:3.7033333333333336%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">o</font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:'Calibri',sans-serif;min-width:fit-content;">Initiation of pivotal clinical trial of INZ-701 in pediatric patients with ABCC6 Deficiency in 2025, subject to regulatory alignment and sufficient funding. </font></div></div>
  <p style="margin-left:16.667%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:12pt;font-family:'Calibri',sans-serif;min-width:fit-content;">&#160;</font></p>
  <div class="item-list-element-wrapper" style="margin-left:3.333%;display:flex;margin-top:0;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.333%;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:3.447919145106397%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#x2022;</font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:12pt;font-family:'Calibri',sans-serif;min-width:fit-content;">Calciphylaxis</font></div></div>
  <div class="item-list-element-wrapper" style="margin-left:10%;display:flex;margin-top:0;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.333%;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:3.7033333333333336%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">o</font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:'Calibri',sans-serif;min-width:fit-content;">Initiation of a pivotal trial of INZ-701 in patients with calciphylaxis in 2025, subject to regulatory alignment and sufficient funding.</font></div></div>
  <p style="margin-left:16.667%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:12pt;font-family:'Calibri',sans-serif;min-width:fit-content;">&#160;</font></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:12pt;font-family:'Calibri',sans-serif;min-width:fit-content;">Third Quarter 2024 Financial Results</font></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:12pt;font-family:'Calibri',sans-serif;min-width:fit-content;">&#160;</font></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:12pt;font-family:'Calibri',sans-serif;min-width:fit-content;">Cash Position and Financial Guidance. </font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:'Calibri',sans-serif;min-width:fit-content;">Cash, cash equivalents, and short-term investments were $131.6 million as of September 30, 2024. Based on its current plans, the Company anticipates its cash, cash equivalents, and short-term investments as of September 30, 2024, will enable the Company to fund cash flow requirements into the fourth quarter of 2025.</font></p>
  <p style="margin-left:6.667%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:12pt;font-family:'Calibri',sans-serif;min-width:fit-content;">&#160;</font></p>
  <div class="item-list-element-wrapper" style="margin-left:3.333%;display:flex;margin-top:0;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.333%;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:3.447919145106397%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#x2022;</font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:12pt;font-family:'Calibri',sans-serif;min-width:fit-content;">Research and Development (R&amp;D) Expenses. </font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:'Calibri',sans-serif;min-width:fit-content;">R&amp;D expenses were $19.9 million for the quarter ended September 30, 2024, compared to $13.3 million for the prior-year period.</font></div></div>
  <p style="margin-left:6.667%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:12pt;font-family:'Calibri',sans-serif;min-width:fit-content;">&#160;</font></p>
  <div class="item-list-element-wrapper" style="margin-left:3.333%;display:flex;margin-top:0;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.333%;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:3.447919145106397%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#x2022;</font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:12pt;font-family:'Calibri',sans-serif;min-width:fit-content;">General Administrative (G&amp;A) Expenses. </font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:'Calibri',sans-serif;min-width:fit-content;">G&amp;A expenses were $5.0 million for the quarter ended September 30, 2024, compared to $4.7 million for the prior-year period. </font></div></div>
  <p style="margin-left:6.667%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:12pt;font-family:'Calibri',sans-serif;min-width:fit-content;">&#160;</font></p>
  <div class="item-list-element-wrapper" style="margin-left:3.333%;display:flex;margin-top:0;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.333%;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:3.447919145106397%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#x2022;</font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:12pt;font-family:'Calibri',sans-serif;min-width:fit-content;">Net Loss. </font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:'Calibri',sans-serif;min-width:fit-content;">Net loss was $24.6 million, or $0.39 net loss per share, for the quarter ended September 30, 2024, compared to $16.6 million or $0.29 net loss per share for the prior-year period.</font></div></div>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:12pt;font-family:'Calibri',sans-serif;min-width:fit-content;">&#160;</font></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:12pt;font-family:'Calibri',sans-serif;min-width:fit-content;">About ENPP1 Deficiency</font></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:'Calibri',sans-serif;min-width:fit-content;">ENPP1 Deficiency is a serious and progressive rare disease that affects blood vessels, soft tissues, and bones. Individuals who present in utero or in infancy are typically diagnosed with generalized arterial calcification of infancy (GACI Type 1), with about 50% of these infants not surviving beyond six months. Children with this condition typically develop rickets, specifically autosomal-recessive hypophosphatemic rickets type 2 (ARHR2), while adolescents and adults may develop osteomalacia, or softened bones. ARHR2 and osteomalacia cause pain and difficulty with movement. Additionally, patients may experience hearing loss, calcification in arteries and joints, and heart problems.</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:'Calibri',sans-serif;min-width:fit-content;"> </font></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:12pt;font-family:'Calibri',sans-serif;min-width:fit-content;">&#160;</font></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:'Calibri',sans-serif;min-width:fit-content;">Biallelic ENPP1 Deficiency affects approximately 1 in 64,000 pregnancies worldwide. Initially, it was believed to only impact individuals with two copies of the mutated gene. However, many individuals with just one copy of the mutated gene (monoallelic ENPP1 Deficiency) also exhibit severe symptoms. This suggests that the worldwide prevalence of ENPP1 Deficiency may be much higher than current estimates, which are based solely on biallelic cases. Currently, there are no approved therapies for ENPP1 Deficiency.</font></p>
  <div class="page-node-content"><div style="z-index:-3;flex-direction:column;display:flex;min-height:1in;justify-content:flex-end;position:relative;"></div></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;page-break-after:always;">
  <div style="padding-top:0.5in;z-index:-3;min-height:1in;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><img src="img4202433_0.jpg" alt="img4202433_0.jpg" style="width:180px;height:90px;"></p></div>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:12pt;font-family:'Calibri',sans-serif;min-width:fit-content;">&#160;</font></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:12pt;font-family:'Calibri',sans-serif;min-width:fit-content;">About ABCC6 Deficiency</font></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:'Calibri',sans-serif;min-width:fit-content;">ABCC6 Deficiency is a progressive and debilitating rare disease that affects blood vessels and soft tissues. Infants with ABCC6 Deficiency are diagnosed with generalized arterial calcification of infancy (GACI Type 2), which is similar to GACI Type 1, the infant form of ENPP1 Deficiency. Pediatric patients who survive beyond the first year of life may develop neurological disease, including strokes, and cardiovascular diseases due to ongoing vascular calcification and stenosis. In older individuals, ABCC6 Deficiency manifests as pseudoxanthoma elasticum (PXE), characterized by abnormal mineralization in blood vessels and soft tissues, affecting the skin, visual function, and vascular system.</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:'Calibri',sans-serif;min-width:fit-content;"> </font></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:12pt;font-family:'Calibri',sans-serif;min-width:fit-content;">&#160;</font></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:'Calibri',sans-serif;min-width:fit-content;">Biallelic ABCC6 Deficiency is estimated to affect 1 in 25,000 to 1 in 50,000 individuals worldwide. Initially, it was believed to only impact individuals with two copies of the mutated gene. However, many people with just one copy of the mutated gene (monoallelic ABCC6 Deficiency) also exhibit severe symptoms. This suggests that the worldwide prevalence of ABCC6 Deficiency may be much higher than current estimates, which are based solely on biallelic cases. Currently, there are no approved therapies for ABCC6 Deficiency.</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:'Calibri',sans-serif;min-width:fit-content;"> </font></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:12pt;font-family:'Calibri',sans-serif;min-width:fit-content;">&#160;</font></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:12pt;font-family:'Calibri',sans-serif;min-width:fit-content;">About Calciphylaxis and the PPi-Adenosine Pathway</font></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:'Calibri',sans-serif;min-width:fit-content;">Calciphylaxis (also known as calcific uremic arteriolopathy, or CUA) is a rare disorder with a high mortality rate that predominantly affects patients with end-stage kidney disease (ESKD). The disease is associated with low levels of inorganic pyrophosphate (PPi) and is characterized by pathologic mineralization (i.e., calcification) and intimal proliferation (the overgrowth of smooth muscle cells inside blood vessels) of the vasculature in the skin and fatty tissue. This leads to poor blood flow, blood clots, painful skin ulcers, serious infections, and often death, with a reported one-year survival rate of approximately 50%. Currently, there are no approved therapies for calciphylaxis. The estimated incidence of calciphylaxis is approximately 3.5 per 1,000 patients with ESKD with approximately 5,000 new patients presenting annually across major addressable markets.</font></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:12pt;font-family:'Calibri',sans-serif;min-width:fit-content;">&#160;</font></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:'Calibri',sans-serif;min-width:fit-content;">The PPi-Adenosine Pathway plays a critical role in regulating both pathologic mineralization and intimal proliferation. The ENPP1 enzyme generates PPi, a potent inhibitor of pathologic mineralization, by hydrolyzing extracellular adenosine triphosphate. Additionally, adenosine, produced by the CD73 enzyme regulates intimal proliferation, preventing the abnormal growth of smooth muscle cells within blood vessels, which can contribute to vascular occlusion. Recent genetic research has shown that polymorphisms in the </font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:'Calibri',sans-serif;font-style:italic;min-width:fit-content;">ENPP1</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:'Calibri',sans-serif;min-width:fit-content;"> or </font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:'Calibri',sans-serif;font-style:italic;min-width:fit-content;">CD73</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:'Calibri',sans-serif;min-width:fit-content;"> genes have been linked to an increased risk of arterial calcification in ESKD patients and/or calciphylaxis, further substantiating the role of the PPi-Adenosine Pathway in this condition.</font></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:'Calibri',sans-serif;min-width:fit-content;">INZ-701 is designed to restore PPi levels and increase adenosine production, addressing both key elements of the PPi-Adenosine Pathway. By normalizing these processes, INZ-701 has the potential to prevent the progression of calciphylaxis, which could offer a promising therapeutic solution for this high-risk and underserved patient population.</font></p>
  <div class="page-node-content"><div style="z-index:-3;flex-direction:column;display:flex;min-height:1in;justify-content:flex-end;position:relative;"></div></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;page-break-after:always;">
  <div style="padding-top:0.5in;z-index:-3;min-height:1in;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><img src="img4202433_0.jpg" alt="img4202433_0.jpg" style="width:180px;height:90px;"></p></div>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:12pt;font-family:'Calibri',sans-serif;min-width:fit-content;">About Inozyme Pharma</font></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:'Calibri',sans-serif;min-width:fit-content;">Inozyme Pharma is a pioneering clinical-stage biopharmaceutical company dedicated to developing innovative therapeutics for rare diseases that affect bone health and blood vessel function. We are experts in the PPi-Adenosine Pathway, where the ENPP1 enzyme generates inorganic pyrophosphate (PPi), which regulates mineralization, and adenosine, which controls intimal proliferation (the overgrowth of smooth muscle cells inside blood vessels). Disruptions in this pathway impact the levels of these molecules, leading to severe musculoskeletal, cardiovascular, and neurological conditions, including ENPP1 Deficiency, ABCC6 Deficiency, calciphylaxis, and ossification of the posterior longitudinal ligament (OPLL).</font></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:12pt;font-family:'Calibri',sans-serif;min-width:fit-content;">&#160;</font></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:'Calibri',sans-serif;min-width:fit-content;">Our lead candidate, INZ-701, is an ENPP1 Fc fusion protein enzyme replacement therapy (ERT) designed to increase PPi and adenosine, enabling the potential treatment of multiple diseases caused by deficiencies in these molecules. It is currently in clinical development for the treatment of ENPP1 Deficiency, ABCC6 Deficiency, and calciphylaxis. By targeting the PPi-Adenosine Pathway, INZ-701 aims to correct pathological mineralization and intimal proliferation, addressing the significant morbidity and mortality in these devastating diseases.</font></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:12pt;font-family:'Calibri',sans-serif;min-width:fit-content;">&#160;</font></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:'Calibri',sans-serif;min-width:fit-content;">For more information, please visit&#x202f;</font><font><font style="white-space:pre-wrap;font-weight:bold;font-size:12pt;font-family:'Calibri',sans-serif;min-width:fit-content;">https://www.inozyme.com/</font></font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:'Calibri',sans-serif;min-width:fit-content;">&#x202f;or follow Inozyme on&#x202f;</font><font><font style="white-space:pre-wrap;font-weight:bold;font-size:12pt;font-family:'Calibri',sans-serif;min-width:fit-content;">LinkedIn</font></font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:'Calibri',sans-serif;min-width:fit-content;">,&#x202f;</font><font><font style="white-space:pre-wrap;font-weight:bold;font-size:12pt;font-family:'Calibri',sans-serif;min-width:fit-content;">X</font></font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:'Calibri',sans-serif;min-width:fit-content;">, and&#x202f;</font><font><font style="white-space:pre-wrap;font-weight:bold;font-size:12pt;font-family:'Calibri',sans-serif;min-width:fit-content;">Facebook</font></font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:'Calibri',sans-serif;min-width:fit-content;">.</font></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:12pt;font-family:'Calibri',sans-serif;min-width:fit-content;">&#160;</font></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:12pt;font-family:'Calibri',sans-serif;min-width:fit-content;">Cautionary Note Regarding Forward-Looking Statements</font></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:'Calibri',sans-serif;min-width:fit-content;">Statements in this press release about future expectations, plans, and prospects, as well as any other statements regarding matters that are not historical facts, may constitute &#34;forward-looking statements&#34; within the meaning of The Private Securities Litigation Reform Act of 1995. These statements include, but are not limited to, statements relating to the initiation, timing, and design of our planned clinical trials, availability of data from clinical trials, the potential benefits of INZ-701, our regulatory strategy, including our planned pathway to approval for the ABCC6 Deficiency and calciphylaxis programs, and the period over which we believe that our existing cash, cash equivalents, and short-term investments will be sufficient to fund our cash flow requirements. The words &#34;anticipate,&#34; &#34;believe,&#34; &#34;continue,&#34; &#34;could,&#34; &#34;estimate,&#34; &#34;expect,&#34; &#34;intend,&#34; &#34;may,&#34; &#34;plan,&#34; &#34;potential,&#34; &#34;predict,&#34; &#34;project,&#34; &#34;should,&#34; &#34;target,&#34; &#34;will,&#34; &#34;would,&#34; and similar expressions are intended to identify forward-looking statements, although not all forward-looking statements contain these identifying words. Any forward-looking statements are based on management's current expectations of future events and are subject to a number of risks and uncertainties that could cause actual results to differ materially and adversely from those set forth in, or implied by, such forward-looking statements. These risks and uncertainties include, but are not limited to, risks associated with the Company's ability to conduct its ongoing clinical trials of INZ-701 for ENPP1 Deficiency, ABCC6 Deficiency, and calciphylaxis; enroll patients in ongoing and planned trials; obtain and maintain necessary approvals from the FDA and other regulatory authorities; continue to advance its product candidates in preclinical studies and clinical trials; replicate in later clinical trials positive results found in preclinical studies and early-stage clinical trials of its product candidates; advance the development of its</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:'Calibri',sans-serif;min-width:fit-content;"> </font></p>
  <div class="page-node-content"><div style="z-index:-3;flex-direction:column;display:flex;min-height:1in;justify-content:flex-end;position:relative;"></div></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;page-break-after:always;">
  <div style="padding-top:0.5in;z-index:-3;min-height:1in;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><img src="img4202433_0.jpg" alt="img4202433_0.jpg" style="width:180px;height:90px;"></p></div>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:'Calibri',sans-serif;min-width:fit-content;">product candidates under the timelines it anticipates in planned and future clinical trials; obtain, maintain, and protect intellectual property rights related to its product candidates; manage expenses; comply with covenants under its outstanding loan agreement; and raise the substantial additional capital needed to achieve its business objectives. For a discussion of other risks and uncertainties, and other important factors, any of which could cause the Company's actual results to differ from those contained in the forward-looking statements, see the &#34;Risk Factors&#34; section in the Company's most recent Annual Report on Form 10-K filed with the Securities and Exchange Commission, as well as discussions of potential risks, uncertainties, and other important factors, in the Company's most recent filings with the Securities and Exchange Commission. In addition, the forward-looking statements included in this press release represent the Company's views as of the date hereof and should not be relied upon as representing the Company's views as of any date subsequent to the date hereof. The Company anticipates that subsequent events and developments will cause the Company's views to change. However, while the Company may elect to update these forward-looking statements at some point in the future, the Company specifically disclaims any obligation to do so.</font></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</font></p>
  <div class="page-node-content"><div style="z-index:-3;flex-direction:column;display:flex;min-height:1in;justify-content:flex-end;position:relative;"></div></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;page-break-after:always;">
  <div style="padding-top:0.5in;z-index:-3;min-height:1in;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><img src="img4202433_0.jpg" alt="img4202433_0.jpg" style="width:180px;height:90px;"></p></div>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:8pt;text-align:center;" id="range_a2_d8"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:12pt;font-family:'Calibri',sans-serif;min-width:fit-content;">Condensed Consolidated Balance Sheet Data<br>(Unaudited)</font></p>
  <table style="border-spacing:0;table-layout:fixed;width:94.0%;border-collapse:separate;">
   <tr style="visibility:collapse;">
    <td style="width:59.552%;box-sizing:content-box;"></td>
    <td style="width:18.864%;box-sizing:content-box;"></td>
    <td style="width:2.721%;box-sizing:content-box;"></td>
    <td style="width:18.864%;box-sizing:content-box;"></td>
   </tr>
   <tr style="height:14.4pt;white-space:pre-wrap;word-break:break-word;">
    <td style="padding-left:0.075in;vertical-align:bottom;padding-right:0.075in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;min-width:fit-content;">&#160;</font></p></td>
    <td style="padding-left:0.075in;vertical-align:bottom;padding-right:0.075in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><font style="white-space:pre-wrap;font-family:'Calibri',sans-serif;min-width:fit-content;">&#160;</font></p></td>
    <td style="padding-left:0.075in;vertical-align:bottom;padding-right:0.075in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-family:'Calibri',sans-serif;min-width:fit-content;">&#160;</font></p></td>
    <td style="padding-left:0.075in;vertical-align:bottom;padding-right:0.075in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-family:'Calibri',sans-serif;min-width:fit-content;">&#160;</font></p></td>
   </tr>
   <tr style="height:27.35pt;white-space:pre-wrap;word-break:break-word;">
    <td style="padding-left:0.075in;vertical-align:bottom;padding-right:0.075in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;min-width:fit-content;">&#160;</font></p></td>
    <td style="padding-left:0.075in;vertical-align:bottom;padding-right:0.075in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-family:'Calibri',sans-serif;min-width:fit-content;">September 30,<br>2024</font></p></td>
    <td style="padding-left:0.075in;vertical-align:bottom;padding-right:0.075in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><font style="white-space:pre-wrap;font-family:'Calibri',sans-serif;min-width:fit-content;">&#160;</font></p></td>
    <td style="padding-left:0.075in;vertical-align:bottom;padding-right:0.075in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-family:'Calibri',sans-serif;min-width:fit-content;">December 31,<br>2023</font></p></td>
   </tr>
   <tr style="height:14.4pt;background-color:#cff0fc;white-space:pre-wrap;word-break:break-word;">
    <td style="padding-left:0.075in;vertical-align:top;padding-right:0.075in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-family:'Calibri',sans-serif;min-width:fit-content;">Cash, cash equivalents and investments</font></p></td>
    <td style="border-top:0.5pt solid;padding-left:0.075in;vertical-align:bottom;padding-right:0.075in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><font style="color:#000000;white-space:pre-wrap;font-family:'Calibri',sans-serif;min-width:fit-content;">&#160;$              131,608</font><font style="color:#000000;white-space:pre-wrap;font-family:'Calibri',sans-serif;min-width:fit-content;"> </font></p></td>
    <td style="border-top:0.5pt solid;padding-left:0.075in;vertical-align:bottom;padding-right:0.075in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><font style="color:#000000;white-space:pre-wrap;font-family:'Calibri',sans-serif;min-width:fit-content;"> </font></p></td>
    <td style="border-top:0.5pt solid;padding-left:0.075in;vertical-align:bottom;padding-right:0.075in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><font style="color:#000000;white-space:pre-wrap;font-family:'Calibri',sans-serif;min-width:fit-content;">&#160;$              188,589</font><font style="color:#000000;white-space:pre-wrap;font-family:'Calibri',sans-serif;min-width:fit-content;"> </font></p></td>
   </tr>
   <tr style="height:14.4pt;white-space:pre-wrap;word-break:break-word;">
    <td style="padding-left:0.075in;vertical-align:top;padding-right:0.075in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-family:'Calibri',sans-serif;min-width:fit-content;">Total assets</font></p></td>
    <td style="padding-left:0.075in;vertical-align:bottom;padding-right:0.075in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><font style="color:#000000;white-space:pre-wrap;font-family:'Calibri',sans-serif;min-width:fit-content;">&#160;$              143,361</font><font style="color:#000000;white-space:pre-wrap;font-family:'Calibri',sans-serif;min-width:fit-content;"> </font></p></td>
    <td style="padding-left:0.075in;vertical-align:bottom;padding-right:0.075in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><font style="white-space:pre-wrap;font-family:'Calibri',sans-serif;min-width:fit-content;">&#160;</font></p></td>
    <td style="padding-left:0.075in;vertical-align:bottom;padding-right:0.075in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><font style="color:#000000;white-space:pre-wrap;font-family:'Calibri',sans-serif;min-width:fit-content;">&#160;$              200,847</font><font style="color:#000000;white-space:pre-wrap;font-family:'Calibri',sans-serif;min-width:fit-content;"> </font></p></td>
   </tr>
   <tr style="height:14.4pt;background-color:#cff0fc;white-space:pre-wrap;word-break:break-word;">
    <td style="padding-left:0.075in;vertical-align:top;padding-right:0.075in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-family:'Calibri',sans-serif;min-width:fit-content;">Total liabilities</font></p></td>
    <td style="padding-left:0.075in;vertical-align:bottom;padding-right:0.075in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><font style="color:#000000;white-space:pre-wrap;font-family:'Calibri',sans-serif;min-width:fit-content;">&#160;$                60,573</font><font style="color:#000000;white-space:pre-wrap;font-family:'Calibri',sans-serif;min-width:fit-content;"> </font></p></td>
    <td style="padding-left:0.075in;vertical-align:bottom;padding-right:0.075in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><font style="white-space:pre-wrap;font-family:'Calibri',sans-serif;min-width:fit-content;">&#160;</font></p></td>
    <td style="padding-left:0.075in;vertical-align:bottom;padding-right:0.075in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><font style="color:#000000;white-space:pre-wrap;font-family:'Calibri',sans-serif;min-width:fit-content;">&#160;$                60,368</font><font style="color:#000000;white-space:pre-wrap;font-family:'Calibri',sans-serif;min-width:fit-content;"> </font></p></td>
   </tr>
   <tr style="height:14.4pt;white-space:pre-wrap;word-break:break-word;">
    <td style="padding-left:0.075in;vertical-align:top;padding-right:0.075in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-family:'Calibri',sans-serif;min-width:fit-content;">Additional paid-in-capital</font></p></td>
    <td style="padding-left:0.075in;vertical-align:bottom;padding-right:0.075in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><font style="color:#000000;white-space:pre-wrap;font-family:'Calibri',sans-serif;min-width:fit-content;">&#160;$              443,476</font><font style="color:#000000;white-space:pre-wrap;font-family:'Calibri',sans-serif;min-width:fit-content;"> </font></p></td>
    <td style="padding-left:0.075in;vertical-align:bottom;padding-right:0.075in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><font style="white-space:pre-wrap;font-family:'Calibri',sans-serif;min-width:fit-content;">&#160;</font></p></td>
    <td style="padding-left:0.075in;vertical-align:bottom;padding-right:0.075in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><font style="color:#000000;white-space:pre-wrap;font-family:'Calibri',sans-serif;min-width:fit-content;">&#160;$              426,362</font><font style="color:#000000;white-space:pre-wrap;font-family:'Calibri',sans-serif;min-width:fit-content;"> </font></p></td>
   </tr>
   <tr style="height:14.4pt;background-color:#cff0fc;white-space:pre-wrap;word-break:break-word;">
    <td style="padding-left:0.075in;vertical-align:top;padding-right:0.075in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-family:'Calibri',sans-serif;min-width:fit-content;">Accumulated deficit</font></p></td>
    <td style="padding-left:0.075in;vertical-align:bottom;padding-right:0.075in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><font style="color:#000000;white-space:pre-wrap;font-family:'Calibri',sans-serif;min-width:fit-content;">&#160;$             (360,880)</font></p></td>
    <td style="padding-left:0.075in;vertical-align:bottom;padding-right:0.075in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><font style="white-space:pre-wrap;font-family:'Calibri',sans-serif;min-width:fit-content;">&#160;</font></p></td>
    <td style="padding-left:0.075in;vertical-align:bottom;padding-right:0.075in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><font style="color:#000000;white-space:pre-wrap;font-family:'Calibri',sans-serif;min-width:fit-content;">&#160;$             (285,930)</font></p></td>
   </tr>
   <tr style="height:14.4pt;white-space:pre-wrap;word-break:break-word;">
    <td style="padding-left:0.075in;vertical-align:top;padding-right:0.075in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-family:'Calibri',sans-serif;min-width:fit-content;">Total stockholders' equity</font></p></td>
    <td style="padding-left:0.075in;vertical-align:bottom;padding-right:0.075in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><font style="color:#000000;white-space:pre-wrap;font-family:'Calibri',sans-serif;min-width:fit-content;">&#160;$                82,788</font><font style="color:#000000;white-space:pre-wrap;font-family:'Calibri',sans-serif;min-width:fit-content;"> </font></p></td>
    <td style="padding-left:0.075in;vertical-align:bottom;padding-right:0.075in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><font style="white-space:pre-wrap;font-family:'Calibri',sans-serif;min-width:fit-content;">&#160;</font></p></td>
    <td style="padding-left:0.075in;vertical-align:bottom;padding-right:0.075in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><font style="color:#000000;white-space:pre-wrap;font-family:'Calibri',sans-serif;min-width:fit-content;">&#160;$              140,479</font><font style="color:#000000;white-space:pre-wrap;font-family:'Calibri',sans-serif;min-width:fit-content;"> </font></p></td>
   </tr>
  </table>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:8pt;text-align:center;"><font style="white-space:pre-wrap;font-size:12pt;font-family:'Calibri',sans-serif;min-width:fit-content;">&#160;</font></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:8pt;text-align:center;"><font style="white-space:pre-wrap;font-size:12pt;font-family:'Calibri',sans-serif;min-width:fit-content;">&#160;</font></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:8pt;text-align:center;" id="range_a1_e43"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:12pt;font-family:'Calibri',sans-serif;min-width:fit-content;">Condensed Consolidated Statements of Operations and Comprehensive Loss<br>(Unaudited)</font></p>
  <table style="border-spacing:0;table-layout:fixed;width:93.0%;border-collapse:separate;">
   <tr style="visibility:collapse;">
    <td style="width:60.588%;box-sizing:content-box;"></td>
    <td style="width:2.539%;box-sizing:content-box;"></td>
    <td style="width:17.097%;box-sizing:content-box;"></td>
    <td style="width:3.619%;box-sizing:content-box;"></td>
    <td style="width:16.157%;box-sizing:content-box;"></td>
   </tr>
   <tr style="height:14.4pt;white-space:pre-wrap;word-break:break-word;">
    <td style="padding-left:0.075in;vertical-align:bottom;padding-right:0.075in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;min-width:fit-content;">&#160;</font></p></td>
    <td style="padding-left:0.075in;vertical-align:bottom;padding-right:0.075in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><font style="white-space:pre-wrap;font-family:'Calibri',sans-serif;min-width:fit-content;">&#160;</font></p></td>
    <td colspan="3" style="padding-left:0.075in;vertical-align:bottom;border-bottom:0.5pt solid;padding-right:0.075in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-family:'Calibri',sans-serif;min-width:fit-content;">Three Months Ended September 30,</font></p></td>
   </tr>
   <tr style="height:14.4pt;white-space:pre-wrap;word-break:break-word;text-align:left;">
    <td style="padding-left:0.075in;vertical-align:bottom;padding-right:0.075in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><font style="white-space:pre-wrap;font-family:'Calibri',sans-serif;min-width:fit-content;">&#160;</font></p></td>
    <td style="padding-left:0.075in;vertical-align:bottom;padding-right:0.075in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><font style="white-space:pre-wrap;font-family:'Calibri',sans-serif;min-width:fit-content;">&#160;</font></p></td>
    <td style="padding-left:0.075in;vertical-align:bottom;border-bottom:0.5pt solid;padding-right:0.075in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-family:'Calibri',sans-serif;min-width:fit-content;">2024</font></p></td>
    <td style="padding-left:0.075in;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;padding-right:0.075in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><font style="white-space:pre-wrap;font-family:'Calibri',sans-serif;min-width:fit-content;">&#160;</font></p></td>
    <td style="padding-left:0.075in;vertical-align:bottom;border-bottom:0.5pt solid;padding-right:0.075in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-family:'Calibri',sans-serif;min-width:fit-content;">2023</font></p></td>
   </tr>
   <tr style="height:14.4pt;background-color:#cff0fc;white-space:pre-wrap;word-break:break-word;">
    <td style="padding-left:0.075in;vertical-align:top;padding-right:0.075in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-family:'Calibri',sans-serif;min-width:fit-content;">Operating expenses:</font></p></td>
    <td style="padding-left:0.075in;vertical-align:bottom;padding-right:0.075in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-family:'Calibri',sans-serif;min-width:fit-content;">&#160;</font></p></td>
    <td style="padding-left:0.075in;vertical-align:bottom;padding-right:0.075in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-family:'Calibri',sans-serif;min-width:fit-content;">&#160;</font></p></td>
    <td style="padding-left:0.075in;vertical-align:bottom;padding-right:0.075in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><font style="white-space:pre-wrap;font-family:'Calibri',sans-serif;min-width:fit-content;">&#160;</font></p></td>
    <td style="padding-left:0.075in;vertical-align:bottom;padding-right:0.075in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-family:'Calibri',sans-serif;min-width:fit-content;">&#160;</font></p></td>
   </tr>
   <tr style="height:14.4pt;white-space:pre-wrap;word-break:break-word;">
    <td style="padding-left:0.075in;vertical-align:top;padding-right:0.075in;"><p style="text-indent:3.707%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-family:'Calibri',sans-serif;min-width:fit-content;">Research and development</font></p></td>
    <td style="padding-left:0.075in;vertical-align:bottom;padding-right:0.075in;"><p style="text-indent:3.707%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-family:'Calibri',sans-serif;min-width:fit-content;">&#160;</font></p></td>
    <td style="padding-left:0.075in;vertical-align:bottom;padding-right:0.075in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><font style="color:#000000;white-space:pre-wrap;font-family:'Calibri',sans-serif;min-width:fit-content;">&#160;$          19,890</font><font style="color:#000000;white-space:pre-wrap;font-family:'Calibri',sans-serif;min-width:fit-content;"> </font></p></td>
    <td style="padding-left:0.075in;vertical-align:bottom;padding-right:0.075in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><font style="white-space:pre-wrap;font-family:'Calibri',sans-serif;min-width:fit-content;">&#160;</font></p></td>
    <td style="padding-left:0.075in;vertical-align:bottom;padding-right:0.075in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><font style="color:#000000;white-space:pre-wrap;font-family:'Calibri',sans-serif;min-width:fit-content;">&#160;$         13,341</font><font style="color:#000000;white-space:pre-wrap;font-family:'Calibri',sans-serif;min-width:fit-content;"> </font></p></td>
   </tr>
   <tr style="height:14.4pt;background-color:#cff0fc;white-space:pre-wrap;word-break:break-word;">
    <td style="padding-left:0.075in;vertical-align:top;padding-right:0.075in;"><p style="text-indent:3.707%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-family:'Calibri',sans-serif;min-width:fit-content;">General and administrative</font></p></td>
    <td style="padding-left:0.075in;vertical-align:bottom;padding-right:0.075in;"><p style="text-indent:3.707%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-family:'Calibri',sans-serif;min-width:fit-content;">&#160;</font></p></td>
    <td style="padding-left:0.075in;vertical-align:bottom;border-bottom:0.5pt solid;padding-right:0.075in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><font style="color:#000000;white-space:pre-wrap;font-family:'Calibri',sans-serif;min-width:fit-content;">&#160;&#160;4,961</font><font style="color:#000000;white-space:pre-wrap;font-family:'Calibri',sans-serif;min-width:fit-content;"> </font></p></td>
    <td style="padding-left:0.075in;vertical-align:bottom;border-bottom:0.5pt solid;padding-right:0.075in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><font style="color:#000000;white-space:pre-wrap;font-family:'Calibri',sans-serif;min-width:fit-content;"> </font></p></td>
    <td style="padding-left:0.075in;vertical-align:bottom;border-bottom:0.5pt solid;padding-right:0.075in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><font style="color:#000000;white-space:pre-wrap;font-family:'Calibri',sans-serif;min-width:fit-content;">&#160;&#160;4,733</font><font style="color:#000000;white-space:pre-wrap;font-family:'Calibri',sans-serif;min-width:fit-content;"> </font></p></td>
   </tr>
   <tr style="height:14.4pt;white-space:pre-wrap;word-break:break-word;">
    <td style="padding-left:0.075in;vertical-align:top;padding-right:0.075in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-family:'Calibri',sans-serif;min-width:fit-content;">Total operating expenses</font></p></td>
    <td style="padding-left:0.075in;vertical-align:bottom;padding-right:0.075in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-family:'Calibri',sans-serif;min-width:fit-content;">&#160;</font></p></td>
    <td style="padding-left:0.075in;vertical-align:bottom;border-bottom:0.5pt solid;padding-right:0.075in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><font style="color:#000000;white-space:pre-wrap;font-family:'Calibri',sans-serif;min-width:fit-content;">&#160;&#160;24,851</font><font style="color:#000000;white-space:pre-wrap;font-family:'Calibri',sans-serif;min-width:fit-content;"> </font></p></td>
    <td style="padding-left:0.075in;vertical-align:bottom;border-bottom:0.5pt solid;padding-right:0.075in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><font style="color:#000000;white-space:pre-wrap;font-family:'Calibri',sans-serif;min-width:fit-content;"> </font></p></td>
    <td style="padding-left:0.075in;vertical-align:bottom;border-bottom:0.5pt solid;padding-right:0.075in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><font style="color:#000000;white-space:pre-wrap;font-family:'Calibri',sans-serif;min-width:fit-content;">&#160;&#160;18,074</font><font style="color:#000000;white-space:pre-wrap;font-family:'Calibri',sans-serif;min-width:fit-content;"> </font></p></td>
   </tr>
   <tr style="height:14.4pt;background-color:#cff0fc;white-space:pre-wrap;word-break:break-word;">
    <td style="padding-left:0.075in;vertical-align:top;padding-right:0.075in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-family:'Calibri',sans-serif;min-width:fit-content;">Loss from operations</font></p></td>
    <td style="padding-left:0.075in;vertical-align:bottom;padding-right:0.075in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-family:'Calibri',sans-serif;min-width:fit-content;">&#160;</font></p></td>
    <td style="padding-left:0.075in;vertical-align:bottom;border-bottom:0.5pt solid;padding-right:0.075in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><font style="color:#000000;white-space:pre-wrap;font-family:'Calibri',sans-serif;min-width:fit-content;">&#160;&#160;(24,851)</font></p></td>
    <td style="padding-left:0.075in;vertical-align:bottom;border-bottom:0.5pt solid;padding-right:0.075in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><font style="color:#000000;white-space:pre-wrap;font-family:'Calibri',sans-serif;min-width:fit-content;"> </font></p></td>
    <td style="padding-left:0.075in;vertical-align:bottom;border-bottom:0.5pt solid;padding-right:0.075in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><font style="color:#000000;white-space:pre-wrap;font-family:'Calibri',sans-serif;min-width:fit-content;">&#160;&#160;(18,074)</font></p></td>
   </tr>
   <tr style="height:14.4pt;white-space:pre-wrap;word-break:break-word;">
    <td style="padding-left:0.075in;vertical-align:top;padding-right:0.075in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-family:'Calibri',sans-serif;min-width:fit-content;">Other income (expense):</font></p></td>
    <td style="padding-left:0.075in;vertical-align:bottom;padding-right:0.075in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-family:'Calibri',sans-serif;min-width:fit-content;">&#160;</font></p></td>
    <td style="padding-left:0.075in;vertical-align:bottom;padding-right:0.075in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-family:'Calibri',sans-serif;min-width:fit-content;">&#160;</font></p></td>
    <td style="padding-left:0.075in;vertical-align:bottom;padding-right:0.075in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><font style="white-space:pre-wrap;font-family:'Calibri',sans-serif;min-width:fit-content;">&#160;</font></p></td>
    <td style="padding-left:0.075in;vertical-align:bottom;padding-right:0.075in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><font style="white-space:pre-wrap;font-family:'Calibri',sans-serif;min-width:fit-content;">&#160;</font></p></td>
   </tr>
   <tr style="height:14.4pt;background-color:#cff0fc;white-space:pre-wrap;word-break:break-word;">
    <td style="padding-left:0.075in;vertical-align:top;padding-right:0.075in;"><p style="text-indent:3.707%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-family:'Calibri',sans-serif;min-width:fit-content;">Interest income</font></p></td>
    <td style="padding-left:0.075in;vertical-align:bottom;padding-right:0.075in;"><p style="text-indent:3.707%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-family:'Calibri',sans-serif;min-width:fit-content;">&#160;</font></p></td>
    <td style="padding-left:0.075in;vertical-align:bottom;padding-right:0.075in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><font style="color:#000000;white-space:pre-wrap;font-family:'Calibri',sans-serif;min-width:fit-content;">&#160;&#160;1,778</font><font style="color:#000000;white-space:pre-wrap;font-family:'Calibri',sans-serif;min-width:fit-content;"> </font></p></td>
    <td style="padding-left:0.075in;vertical-align:bottom;padding-right:0.075in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><font style="white-space:pre-wrap;font-family:'Calibri',sans-serif;min-width:fit-content;">&#160;</font></p></td>
    <td style="padding-left:0.075in;vertical-align:bottom;padding-right:0.075in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><font style="color:#000000;white-space:pre-wrap;font-family:'Calibri',sans-serif;min-width:fit-content;">&#160;&#160;2,369</font><font style="color:#000000;white-space:pre-wrap;font-family:'Calibri',sans-serif;min-width:fit-content;"> </font></p></td>
   </tr>
   <tr style="height:14.4pt;white-space:pre-wrap;word-break:break-word;">
    <td style="padding-left:0.075in;vertical-align:top;padding-right:0.075in;"><p style="text-indent:3.707%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-family:'Calibri',sans-serif;min-width:fit-content;">Interest expense</font></p></td>
    <td style="padding-left:0.075in;vertical-align:bottom;padding-right:0.075in;"><p style="text-indent:3.707%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-family:'Calibri',sans-serif;min-width:fit-content;">&#160;</font></p></td>
    <td style="padding-left:0.075in;vertical-align:bottom;padding-right:0.075in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><font style="color:#000000;white-space:pre-wrap;font-family:'Calibri',sans-serif;min-width:fit-content;">&#160;&#160;(1,416)</font></p></td>
    <td style="padding-left:0.075in;vertical-align:bottom;padding-right:0.075in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><font style="white-space:pre-wrap;font-family:'Calibri',sans-serif;min-width:fit-content;">&#160;</font></p></td>
    <td style="padding-left:0.075in;vertical-align:bottom;padding-right:0.075in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><font style="color:#000000;white-space:pre-wrap;font-family:'Calibri',sans-serif;min-width:fit-content;">&#160;&#160;(953)</font></p></td>
   </tr>
   <tr style="height:14.4pt;background-color:#cff0fc;white-space:pre-wrap;word-break:break-word;">
    <td style="padding-left:0.075in;vertical-align:top;padding-right:0.075in;"><p style="text-indent:3.707%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-family:'Calibri',sans-serif;min-width:fit-content;">Other (expense)income, net</font></p></td>
    <td style="padding-left:0.075in;vertical-align:bottom;padding-right:0.075in;"><p style="text-indent:3.707%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-family:'Calibri',sans-serif;min-width:fit-content;">&#160;</font></p></td>
    <td style="padding-left:0.075in;vertical-align:bottom;border-bottom:0.5pt solid;padding-right:0.075in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><font style="color:#000000;white-space:pre-wrap;font-family:'Calibri',sans-serif;min-width:fit-content;">&#160;&#160;(81)</font></p></td>
    <td style="padding-left:0.075in;vertical-align:bottom;border-bottom:0.5pt solid;padding-right:0.075in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><font style="color:#000000;white-space:pre-wrap;font-family:'Calibri',sans-serif;min-width:fit-content;"> </font></p></td>
    <td style="padding-left:0.075in;vertical-align:bottom;border-bottom:0.5pt solid;padding-right:0.075in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><font style="color:#000000;white-space:pre-wrap;font-family:'Calibri',sans-serif;min-width:fit-content;">&#160;&#160;20</font><font style="color:#000000;white-space:pre-wrap;font-family:'Calibri',sans-serif;min-width:fit-content;"> </font></p></td>
   </tr>
   <tr style="height:14.4pt;white-space:pre-wrap;word-break:break-word;">
    <td style="padding-left:0.075in;vertical-align:top;padding-right:0.075in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-family:'Calibri',sans-serif;min-width:fit-content;">Other income, net</font></p></td>
    <td style="padding-left:0.075in;vertical-align:bottom;padding-right:0.075in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-family:'Calibri',sans-serif;min-width:fit-content;">&#160;</font></p></td>
    <td style="padding-left:0.075in;vertical-align:bottom;border-bottom:0.5pt solid;padding-right:0.075in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><font style="color:#000000;white-space:pre-wrap;font-family:'Calibri',sans-serif;min-width:fit-content;">&#160;&#160;281</font><font style="color:#000000;white-space:pre-wrap;font-family:'Calibri',sans-serif;min-width:fit-content;"> </font></p></td>
    <td style="padding-left:0.075in;vertical-align:bottom;border-bottom:0.5pt solid;padding-right:0.075in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><font style="color:#000000;white-space:pre-wrap;font-family:'Calibri',sans-serif;min-width:fit-content;"> </font></p></td>
    <td style="padding-left:0.075in;vertical-align:bottom;border-bottom:0.5pt solid;padding-right:0.075in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><font style="color:#000000;white-space:pre-wrap;font-family:'Calibri',sans-serif;min-width:fit-content;">&#160;&#160;1,436</font><font style="color:#000000;white-space:pre-wrap;font-family:'Calibri',sans-serif;min-width:fit-content;"> </font></p></td>
   </tr>
   <tr style="height:15.1pt;background-color:#cff0fc;white-space:pre-wrap;word-break:break-word;">
    <td style="padding-left:0.075in;vertical-align:top;padding-right:0.075in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-family:'Calibri',sans-serif;min-width:fit-content;">Net loss</font></p></td>
    <td style="padding-left:0.075in;vertical-align:bottom;padding-right:0.075in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-family:'Calibri',sans-serif;min-width:fit-content;">&#160;</font></p></td>
    <td style="padding-left:0.075in;vertical-align:bottom;border-bottom:2.25pt double;padding-right:0.075in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><font style="color:#000000;white-space:pre-wrap;font-family:'Calibri',sans-serif;min-width:fit-content;">&#160;$         (24,570)</font></p></td>
    <td style="padding-left:0.075in;vertical-align:bottom;border-bottom:2.25pt double;padding-right:0.075in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><font style="color:#000000;white-space:pre-wrap;font-family:'Calibri',sans-serif;min-width:fit-content;"> </font></p></td>
    <td style="padding-left:0.075in;vertical-align:bottom;border-bottom:2.25pt double;padding-right:0.075in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><font style="color:#000000;white-space:pre-wrap;font-family:'Calibri',sans-serif;min-width:fit-content;">&#160;$       (16,638)</font></p></td>
   </tr>
   <tr style="height:15.1pt;white-space:pre-wrap;word-break:break-word;">
    <td style="padding-left:0.075in;vertical-align:top;padding-right:0.075in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-family:'Calibri',sans-serif;min-width:fit-content;">Other comprehensive income (loss):</font></p></td>
    <td style="padding-left:0.075in;vertical-align:bottom;padding-right:0.075in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-family:'Calibri',sans-serif;min-width:fit-content;">&#160;</font></p></td>
    <td style="padding-left:0.075in;vertical-align:bottom;padding-right:0.075in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-family:'Calibri',sans-serif;min-width:fit-content;">&#160;</font></p></td>
    <td style="padding-left:0.075in;vertical-align:bottom;padding-right:0.075in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><font style="white-space:pre-wrap;font-family:'Calibri',sans-serif;min-width:fit-content;">&#160;</font></p></td>
    <td style="padding-left:0.075in;vertical-align:bottom;padding-right:0.075in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><font style="white-space:pre-wrap;font-family:'Calibri',sans-serif;min-width:fit-content;">&#160;</font></p></td>
   </tr>
   <tr style="height:14.4pt;background-color:#cff0fc;white-space:pre-wrap;word-break:break-word;">
    <td style="padding-left:0.075in;vertical-align:top;padding-right:0.075in;"><p style="text-indent:3.707%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-family:'Calibri',sans-serif;min-width:fit-content;">Unrealized gains on available-for-sale securities</font></p></td>
    <td style="padding-left:0.075in;vertical-align:bottom;padding-right:0.075in;"><p style="text-indent:3.707%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-family:'Calibri',sans-serif;min-width:fit-content;">&#160;</font></p></td>
    <td style="padding-left:0.075in;vertical-align:bottom;padding-right:0.075in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><font style="color:#000000;white-space:pre-wrap;font-family:'Calibri',sans-serif;min-width:fit-content;">&#160;&#160;290</font><font style="color:#000000;white-space:pre-wrap;font-family:'Calibri',sans-serif;min-width:fit-content;"> </font></p></td>
    <td style="padding-left:0.075in;vertical-align:bottom;padding-right:0.075in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><font style="white-space:pre-wrap;font-family:'Calibri',sans-serif;min-width:fit-content;">&#160;</font></p></td>
    <td style="padding-left:0.075in;vertical-align:bottom;padding-right:0.075in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><font style="color:#000000;white-space:pre-wrap;font-family:'Calibri',sans-serif;min-width:fit-content;">&#160;&#160;53</font><font style="color:#000000;white-space:pre-wrap;font-family:'Calibri',sans-serif;min-width:fit-content;"> </font></p></td>
   </tr>
   <tr style="height:14.4pt;white-space:pre-wrap;word-break:break-word;">
    <td style="padding-left:0.075in;vertical-align:top;padding-right:0.075in;"><p style="text-indent:3.707%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-family:'Calibri',sans-serif;min-width:fit-content;">Foreign currency translation adjustment</font></p></td>
    <td style="padding-left:0.075in;vertical-align:bottom;padding-right:0.075in;"><p style="text-indent:3.707%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-family:'Calibri',sans-serif;min-width:fit-content;">&#160;</font></p></td>
    <td style="padding-left:0.075in;vertical-align:bottom;padding-right:0.075in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><font style="color:#000000;white-space:pre-wrap;font-family:'Calibri',sans-serif;min-width:fit-content;">&#160;&#160;(1)</font></p></td>
    <td style="padding-left:0.075in;vertical-align:bottom;padding-right:0.075in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><font style="white-space:pre-wrap;font-family:'Calibri',sans-serif;min-width:fit-content;">&#160;</font></p></td>
    <td style="padding-left:0.075in;vertical-align:bottom;padding-right:0.075in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><font style="color:#000000;white-space:pre-wrap;font-family:'Calibri',sans-serif;min-width:fit-content;">&#160;&#160;(182)</font></p></td>
   </tr>
   <tr style="height:14.4pt;background-color:#cff0fc;white-space:pre-wrap;word-break:break-word;">
    <td style="padding-left:0.075in;vertical-align:top;padding-right:0.075in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-family:'Calibri',sans-serif;min-width:fit-content;">Total other comprehensive income (loss)</font></p></td>
    <td style="padding-left:0.075in;vertical-align:bottom;padding-right:0.075in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-family:'Calibri',sans-serif;min-width:fit-content;">&#160;</font></p></td>
    <td style="border-top:0.5pt solid;padding-left:0.075in;vertical-align:bottom;border-bottom:0.5pt solid;padding-right:0.075in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><font style="color:#000000;white-space:pre-wrap;font-family:'Calibri',sans-serif;min-width:fit-content;">&#160;&#160;289</font><font style="color:#000000;white-space:pre-wrap;font-family:'Calibri',sans-serif;min-width:fit-content;"> </font></p></td>
    <td style="border-top:0.5pt solid;padding-left:0.075in;vertical-align:bottom;border-bottom:0.5pt solid;padding-right:0.075in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><font style="color:#000000;white-space:pre-wrap;font-family:'Calibri',sans-serif;min-width:fit-content;"> </font></p></td>
    <td style="border-top:0.5pt solid;padding-left:0.075in;vertical-align:bottom;border-bottom:0.5pt solid;padding-right:0.075in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><font style="color:#000000;white-space:pre-wrap;font-family:'Calibri',sans-serif;min-width:fit-content;">&#160;&#160;(129)</font></p></td>
   </tr>
   <tr style="height:15.1pt;white-space:pre-wrap;word-break:break-word;">
    <td style="padding-left:0.075in;vertical-align:top;padding-right:0.075in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-family:'Calibri',sans-serif;min-width:fit-content;">Comprehensive loss</font></p></td>
    <td style="padding-left:0.075in;vertical-align:bottom;padding-right:0.075in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-family:'Calibri',sans-serif;min-width:fit-content;">&#160;</font></p></td>
    <td style="padding-left:0.075in;vertical-align:bottom;border-bottom:2.25pt double;padding-right:0.075in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><font style="color:#000000;white-space:pre-wrap;font-family:'Calibri',sans-serif;min-width:fit-content;">&#160;$         (24,281)</font></p></td>
    <td style="padding-left:0.075in;vertical-align:bottom;border-bottom:2.25pt double;padding-right:0.075in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><font style="color:#000000;white-space:pre-wrap;font-family:'Calibri',sans-serif;min-width:fit-content;"> </font></p></td>
    <td style="padding-left:0.075in;vertical-align:bottom;border-bottom:2.25pt double;padding-right:0.075in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><font style="color:#000000;white-space:pre-wrap;font-family:'Calibri',sans-serif;min-width:fit-content;">&#160;$       (16,767)</font></p></td>
   </tr>
   <tr style="height:27.35pt;background-color:#cff0fc;white-space:pre-wrap;word-break:break-word;">
    <td style="padding-left:0.075in;vertical-align:top;padding-right:0.075in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-family:'Calibri',sans-serif;min-width:fit-content;">Net loss attributable to common stockholders&#x2014;basic<br>&#160;&#160;&#160;and diluted</font></p></td>
    <td style="padding-left:0.075in;vertical-align:bottom;padding-right:0.075in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-family:'Calibri',sans-serif;min-width:fit-content;">&#160;</font></p></td>
    <td style="padding-left:0.075in;vertical-align:bottom;border-bottom:2.25pt double;padding-right:0.075in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><font style="color:#000000;white-space:pre-wrap;font-family:'Calibri',sans-serif;min-width:fit-content;">&#160;$         (24,570)</font></p></td>
    <td style="padding-left:0.075in;vertical-align:bottom;border-bottom:2.25pt double;padding-right:0.075in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><font style="color:#000000;white-space:pre-wrap;font-family:'Calibri',sans-serif;min-width:fit-content;"> </font></p></td>
    <td style="padding-left:0.075in;vertical-align:bottom;border-bottom:2.25pt double;padding-right:0.075in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><font style="color:#000000;white-space:pre-wrap;font-family:'Calibri',sans-serif;min-width:fit-content;">&#160;$       (16,638)</font></p></td>
   </tr>
   <tr style="height:27.35pt;white-space:pre-wrap;word-break:break-word;">
    <td style="padding-left:0.075in;vertical-align:top;padding-right:0.075in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-family:'Calibri',sans-serif;min-width:fit-content;">Net loss per share attributable to common<br>&#160;&#160;&#160;stockholders&#x2014;basic and diluted</font></p></td>
    <td style="padding-left:0.075in;vertical-align:bottom;padding-right:0.075in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-family:'Calibri',sans-serif;min-width:fit-content;">&#160;</font></p></td>
    <td style="padding-left:0.075in;vertical-align:bottom;border-bottom:2.25pt double;padding-right:0.075in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><font style="color:#000000;white-space:pre-wrap;font-family:'Calibri',sans-serif;min-width:fit-content;">&#160;$             (0.39)</font></p></td>
    <td style="padding-left:0.075in;vertical-align:bottom;border-bottom:2.25pt double;padding-right:0.075in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><font style="color:#000000;white-space:pre-wrap;font-family:'Calibri',sans-serif;min-width:fit-content;"> </font></p></td>
    <td style="padding-left:0.075in;vertical-align:bottom;border-bottom:2.25pt double;padding-right:0.075in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><font style="color:#000000;white-space:pre-wrap;font-family:'Calibri',sans-serif;min-width:fit-content;">&#160;$           (0.29)</font></p></td>
   </tr>
  </table>
  <div class="page-node-content"><div style="z-index:-3;flex-direction:column;display:flex;min-height:1in;justify-content:flex-end;position:relative;"></div></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;page-break-after:always;">
  <div style="padding-top:0.5in;z-index:-3;min-height:1in;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><img src="img4202433_0.jpg" alt="img4202433_0.jpg" style="width:180px;height:90px;"></p></div>
  <table style="border-spacing:0;table-layout:fixed;width:93.0%;border-collapse:separate;">
   <tr style="visibility:collapse;">
    <td style="width:60.588%;box-sizing:content-box;"></td>
    <td style="width:2.539%;box-sizing:content-box;"></td>
    <td style="width:17.097%;box-sizing:content-box;"></td>
    <td style="width:3.619%;box-sizing:content-box;"></td>
    <td style="width:16.157%;box-sizing:content-box;"></td>
   </tr>
   <tr style="height:27.35pt;background-color:#cff0fc;white-space:pre-wrap;word-break:break-word;">
    <td style="padding-left:0.075in;vertical-align:top;padding-right:0.075in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-family:'Calibri',sans-serif;min-width:fit-content;">Weighted-average common shares outstanding&#x2014;basic<br>&#160;&#160;&#160;and diluted</font></p></td>
    <td style="padding-left:0.075in;vertical-align:bottom;padding-right:0.075in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-family:'Calibri',sans-serif;min-width:fit-content;">&#160;</font></p></td>
    <td style="border-top:2.25pt double;padding-left:0.075in;vertical-align:bottom;border-bottom:2.25pt double;padding-right:0.075in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><font style="color:#000000;white-space:pre-wrap;font-family:'Calibri',sans-serif;min-width:fit-content;">&#160;&#160;63,276,851</font><font style="color:#000000;white-space:pre-wrap;font-family:'Calibri',sans-serif;min-width:fit-content;"> </font></p></td>
    <td style="border-top:2.25pt double;padding-left:0.075in;vertical-align:bottom;border-bottom:2.25pt double;padding-right:0.075in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><font style="color:#000000;white-space:pre-wrap;font-family:'Calibri',sans-serif;min-width:fit-content;"> </font></p></td>
    <td style="border-top:2.25pt double;padding-left:0.075in;vertical-align:bottom;border-bottom:2.25pt double;padding-right:0.075in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><font style="color:#000000;white-space:pre-wrap;font-family:'Calibri',sans-serif;min-width:fit-content;">&#160;&#160;56,758,395</font><font style="color:#000000;white-space:pre-wrap;font-family:'Calibri',sans-serif;min-width:fit-content;"> </font></p></td>
   </tr>
   <tr style="height:15.1pt;white-space:pre-wrap;word-break:break-word;">
    <td style="padding-left:0.075in;vertical-align:bottom;padding-right:0.075in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><font style="white-space:pre-wrap;font-family:'Calibri',sans-serif;min-width:fit-content;">&#160;</font></p></td>
    <td style="padding-left:0.075in;vertical-align:bottom;padding-right:0.075in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-family:'Calibri',sans-serif;min-width:fit-content;">&#160;</font></p></td>
    <td style="padding-left:0.075in;vertical-align:bottom;padding-right:0.075in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-family:'Calibri',sans-serif;min-width:fit-content;">&#160;</font></p></td>
    <td style="padding-left:0.075in;vertical-align:bottom;padding-right:0.075in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-family:'Calibri',sans-serif;min-width:fit-content;">&#160;</font></p></td>
    <td style="padding-left:0.075in;vertical-align:bottom;padding-right:0.075in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-family:'Calibri',sans-serif;min-width:fit-content;">&#160;</font></p></td>
   </tr>
   <tr style="height:14.4pt;white-space:pre-wrap;word-break:break-word;">
    <td style="padding-left:0.075in;vertical-align:bottom;padding-right:0.075in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-family:'Calibri',sans-serif;min-width:fit-content;">&#160;</font></p></td>
    <td style="padding-left:0.075in;vertical-align:bottom;padding-right:0.075in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><font style="white-space:pre-wrap;font-family:'Calibri',sans-serif;min-width:fit-content;">&#160;</font></p></td>
    <td colspan="3" style="padding-left:0.075in;vertical-align:bottom;border-bottom:0.5pt solid;padding-right:0.075in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-family:'Calibri',sans-serif;min-width:fit-content;">Nine Months Ended September 30,</font></p></td>
   </tr>
   <tr style="height:14.4pt;white-space:pre-wrap;word-break:break-word;text-align:left;">
    <td style="padding-left:0.075in;vertical-align:bottom;padding-right:0.075in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><font style="white-space:pre-wrap;font-family:'Calibri',sans-serif;min-width:fit-content;">&#160;</font></p></td>
    <td style="padding-left:0.075in;vertical-align:bottom;padding-right:0.075in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><font style="white-space:pre-wrap;font-family:'Calibri',sans-serif;min-width:fit-content;">&#160;</font></p></td>
    <td style="padding-left:0.075in;vertical-align:bottom;border-bottom:0.5pt solid;padding-right:0.075in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-family:'Calibri',sans-serif;min-width:fit-content;">2024</font></p></td>
    <td style="padding-left:0.075in;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;padding-right:0.075in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><font style="white-space:pre-wrap;font-family:'Calibri',sans-serif;min-width:fit-content;">&#160;</font></p></td>
    <td style="padding-left:0.075in;vertical-align:bottom;border-bottom:0.5pt solid;padding-right:0.075in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-family:'Calibri',sans-serif;min-width:fit-content;">2023</font></p></td>
   </tr>
   <tr style="height:14.4pt;white-space:pre-wrap;word-break:break-word;">
    <td style="padding-left:0.075in;vertical-align:top;padding-right:0.075in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-family:'Calibri',sans-serif;min-width:fit-content;">Operating expenses:</font></p></td>
    <td style="padding-left:0.075in;vertical-align:bottom;padding-right:0.075in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-family:'Calibri',sans-serif;min-width:fit-content;">&#160;</font></p></td>
    <td style="padding-left:0.075in;vertical-align:bottom;padding-right:0.075in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-family:'Calibri',sans-serif;min-width:fit-content;">&#160;</font></p></td>
    <td style="padding-left:0.075in;vertical-align:bottom;padding-right:0.075in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><font style="white-space:pre-wrap;font-family:'Calibri',sans-serif;min-width:fit-content;">&#160;</font></p></td>
    <td style="padding-left:0.075in;vertical-align:bottom;padding-right:0.075in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-family:'Calibri',sans-serif;min-width:fit-content;">&#160;</font></p></td>
   </tr>
   <tr style="height:14.4pt;background-color:#cff0fc;white-space:pre-wrap;word-break:break-word;">
    <td style="padding-left:0.075in;vertical-align:top;padding-right:0.075in;"><p style="text-indent:3.707%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-family:'Calibri',sans-serif;min-width:fit-content;">Research and development</font></p></td>
    <td style="padding-left:0.075in;vertical-align:bottom;padding-right:0.075in;"><p style="text-indent:3.707%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-family:'Calibri',sans-serif;min-width:fit-content;">&#160;</font></p></td>
    <td style="padding-left:0.075in;vertical-align:bottom;padding-right:0.075in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><font style="color:#000000;white-space:pre-wrap;font-family:'Calibri',sans-serif;min-width:fit-content;">&#160;$          60,758</font><font style="color:#000000;white-space:pre-wrap;font-family:'Calibri',sans-serif;min-width:fit-content;"> </font></p></td>
    <td style="padding-left:0.075in;vertical-align:bottom;padding-right:0.075in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><font style="white-space:pre-wrap;font-family:'Calibri',sans-serif;min-width:fit-content;">&#160;</font></p></td>
    <td style="padding-left:0.075in;vertical-align:bottom;padding-right:0.075in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><font style="color:#000000;white-space:pre-wrap;font-family:'Calibri',sans-serif;min-width:fit-content;">&#160;$         36,864</font><font style="color:#000000;white-space:pre-wrap;font-family:'Calibri',sans-serif;min-width:fit-content;"> </font></p></td>
   </tr>
   <tr style="height:14.4pt;white-space:pre-wrap;word-break:break-word;">
    <td style="padding-left:0.075in;vertical-align:top;padding-right:0.075in;"><p style="text-indent:3.707%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-family:'Calibri',sans-serif;min-width:fit-content;">General and administrative</font></p></td>
    <td style="padding-left:0.075in;vertical-align:bottom;padding-right:0.075in;"><p style="text-indent:3.707%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-family:'Calibri',sans-serif;min-width:fit-content;">&#160;</font></p></td>
    <td style="padding-left:0.075in;vertical-align:bottom;border-bottom:0.5pt solid;padding-right:0.075in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><font style="color:#000000;white-space:pre-wrap;font-family:'Calibri',sans-serif;min-width:fit-content;">&#160;&#160;16,101</font><font style="color:#000000;white-space:pre-wrap;font-family:'Calibri',sans-serif;min-width:fit-content;"> </font></p></td>
    <td style="padding-left:0.075in;vertical-align:bottom;border-bottom:0.5pt solid;padding-right:0.075in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><font style="color:#000000;white-space:pre-wrap;font-family:'Calibri',sans-serif;min-width:fit-content;"> </font></p></td>
    <td style="padding-left:0.075in;vertical-align:bottom;border-bottom:0.5pt solid;padding-right:0.075in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><font style="color:#000000;white-space:pre-wrap;font-family:'Calibri',sans-serif;min-width:fit-content;">&#160;&#160;15,973</font><font style="color:#000000;white-space:pre-wrap;font-family:'Calibri',sans-serif;min-width:fit-content;"> </font></p></td>
   </tr>
   <tr style="height:14.4pt;background-color:#cff0fc;white-space:pre-wrap;word-break:break-word;">
    <td style="padding-left:0.075in;vertical-align:top;padding-right:0.075in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-family:'Calibri',sans-serif;min-width:fit-content;">Total operating expenses</font></p></td>
    <td style="padding-left:0.075in;vertical-align:bottom;padding-right:0.075in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-family:'Calibri',sans-serif;min-width:fit-content;">&#160;</font></p></td>
    <td style="padding-left:0.075in;vertical-align:bottom;border-bottom:0.5pt solid;padding-right:0.075in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><font style="color:#000000;white-space:pre-wrap;font-family:'Calibri',sans-serif;min-width:fit-content;">&#160;&#160;76,859</font><font style="color:#000000;white-space:pre-wrap;font-family:'Calibri',sans-serif;min-width:fit-content;"> </font></p></td>
    <td style="padding-left:0.075in;vertical-align:bottom;border-bottom:0.5pt solid;padding-right:0.075in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><font style="color:#000000;white-space:pre-wrap;font-family:'Calibri',sans-serif;min-width:fit-content;"> </font></p></td>
    <td style="padding-left:0.075in;vertical-align:bottom;border-bottom:0.5pt solid;padding-right:0.075in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><font style="color:#000000;white-space:pre-wrap;font-family:'Calibri',sans-serif;min-width:fit-content;">&#160;&#160;52,837</font><font style="color:#000000;white-space:pre-wrap;font-family:'Calibri',sans-serif;min-width:fit-content;"> </font></p></td>
   </tr>
   <tr style="height:14.4pt;white-space:pre-wrap;word-break:break-word;">
    <td style="padding-left:0.075in;vertical-align:top;padding-right:0.075in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-family:'Calibri',sans-serif;min-width:fit-content;">Loss from operations</font></p></td>
    <td style="padding-left:0.075in;vertical-align:bottom;padding-right:0.075in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-family:'Calibri',sans-serif;min-width:fit-content;">&#160;</font></p></td>
    <td style="padding-left:0.075in;vertical-align:bottom;border-bottom:0.5pt solid;padding-right:0.075in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><font style="color:#000000;white-space:pre-wrap;font-family:'Calibri',sans-serif;min-width:fit-content;">&#160;&#160;(76,859)</font></p></td>
    <td style="padding-left:0.075in;vertical-align:bottom;border-bottom:0.5pt solid;padding-right:0.075in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><font style="color:#000000;white-space:pre-wrap;font-family:'Calibri',sans-serif;min-width:fit-content;"> </font></p></td>
    <td style="padding-left:0.075in;vertical-align:bottom;border-bottom:0.5pt solid;padding-right:0.075in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><font style="color:#000000;white-space:pre-wrap;font-family:'Calibri',sans-serif;min-width:fit-content;">&#160;&#160;(52,837)</font></p></td>
   </tr>
   <tr style="height:14.4pt;background-color:#cff0fc;white-space:pre-wrap;word-break:break-word;">
    <td style="padding-left:0.075in;vertical-align:top;padding-right:0.075in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-family:'Calibri',sans-serif;min-width:fit-content;">Other income (expense):</font></p></td>
    <td style="padding-left:0.075in;vertical-align:bottom;padding-right:0.075in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-family:'Calibri',sans-serif;min-width:fit-content;">&#160;</font></p></td>
    <td style="padding-left:0.075in;vertical-align:bottom;padding-right:0.075in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-family:'Calibri',sans-serif;min-width:fit-content;">&#160;</font></p></td>
    <td style="padding-left:0.075in;vertical-align:bottom;padding-right:0.075in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><font style="white-space:pre-wrap;font-family:'Calibri',sans-serif;min-width:fit-content;">&#160;</font></p></td>
    <td style="padding-left:0.075in;vertical-align:bottom;padding-right:0.075in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><font style="white-space:pre-wrap;font-family:'Calibri',sans-serif;min-width:fit-content;">&#160;</font></p></td>
   </tr>
   <tr style="height:14.4pt;white-space:pre-wrap;word-break:break-word;">
    <td style="padding-left:0.075in;vertical-align:top;padding-right:0.075in;"><p style="text-indent:3.707%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-family:'Calibri',sans-serif;min-width:fit-content;">Interest income</font></p></td>
    <td style="padding-left:0.075in;vertical-align:bottom;padding-right:0.075in;"><p style="text-indent:3.707%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-family:'Calibri',sans-serif;min-width:fit-content;">&#160;</font></p></td>
    <td style="padding-left:0.075in;vertical-align:bottom;padding-right:0.075in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><font style="color:#000000;white-space:pre-wrap;font-family:'Calibri',sans-serif;min-width:fit-content;">&#160;&#160;6,182</font><font style="color:#000000;white-space:pre-wrap;font-family:'Calibri',sans-serif;min-width:fit-content;"> </font></p></td>
    <td style="padding-left:0.075in;vertical-align:bottom;padding-right:0.075in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><font style="white-space:pre-wrap;font-family:'Calibri',sans-serif;min-width:fit-content;">&#160;</font></p></td>
    <td style="padding-left:0.075in;vertical-align:bottom;padding-right:0.075in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><font style="color:#000000;white-space:pre-wrap;font-family:'Calibri',sans-serif;min-width:fit-content;">&#160;&#160;5,306</font><font style="color:#000000;white-space:pre-wrap;font-family:'Calibri',sans-serif;min-width:fit-content;"> </font></p></td>
   </tr>
   <tr style="height:14.4pt;background-color:#cff0fc;white-space:pre-wrap;word-break:break-word;">
    <td style="padding-left:0.075in;vertical-align:top;padding-right:0.075in;"><p style="text-indent:3.707%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-family:'Calibri',sans-serif;min-width:fit-content;">Interest expense</font></p></td>
    <td style="padding-left:0.075in;vertical-align:bottom;padding-right:0.075in;"><p style="text-indent:3.707%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-family:'Calibri',sans-serif;min-width:fit-content;">&#160;</font></p></td>
    <td style="padding-left:0.075in;vertical-align:bottom;padding-right:0.075in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><font style="color:#000000;white-space:pre-wrap;font-family:'Calibri',sans-serif;min-width:fit-content;">&#160;&#160;(4,136)</font></p></td>
    <td style="padding-left:0.075in;vertical-align:bottom;padding-right:0.075in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><font style="white-space:pre-wrap;font-family:'Calibri',sans-serif;min-width:fit-content;">&#160;</font></p></td>
    <td style="padding-left:0.075in;vertical-align:bottom;padding-right:0.075in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><font style="color:#000000;white-space:pre-wrap;font-family:'Calibri',sans-serif;min-width:fit-content;">&#160;&#160;(2,052)</font></p></td>
   </tr>
   <tr style="height:14.4pt;white-space:pre-wrap;word-break:break-word;">
    <td style="padding-left:0.075in;vertical-align:top;padding-right:0.075in;"><p style="text-indent:3.707%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-family:'Calibri',sans-serif;min-width:fit-content;">Other expense, net</font></p></td>
    <td style="padding-left:0.075in;vertical-align:bottom;padding-right:0.075in;"><p style="text-indent:3.707%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-family:'Calibri',sans-serif;min-width:fit-content;">&#160;</font></p></td>
    <td style="padding-left:0.075in;vertical-align:bottom;border-bottom:0.5pt solid;padding-right:0.075in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><font style="color:#000000;white-space:pre-wrap;font-family:'Calibri',sans-serif;min-width:fit-content;">&#160;&#160;(137)</font></p></td>
    <td style="padding-left:0.075in;vertical-align:bottom;border-bottom:0.5pt solid;padding-right:0.075in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><font style="color:#000000;white-space:pre-wrap;font-family:'Calibri',sans-serif;min-width:fit-content;"> </font></p></td>
    <td style="padding-left:0.075in;vertical-align:bottom;border-bottom:0.5pt solid;padding-right:0.075in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><font style="color:#000000;white-space:pre-wrap;font-family:'Calibri',sans-serif;min-width:fit-content;">&#160;&#160;(42)</font></p></td>
   </tr>
   <tr style="height:14.4pt;background-color:#cff0fc;white-space:pre-wrap;word-break:break-word;">
    <td style="padding-left:0.075in;vertical-align:top;padding-right:0.075in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-family:'Calibri',sans-serif;min-width:fit-content;">Other income (expense), net</font></p></td>
    <td style="padding-left:0.075in;vertical-align:bottom;padding-right:0.075in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-family:'Calibri',sans-serif;min-width:fit-content;">&#160;</font></p></td>
    <td style="padding-left:0.075in;vertical-align:bottom;border-bottom:0.5pt solid;padding-right:0.075in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><font style="color:#000000;white-space:pre-wrap;font-family:'Calibri',sans-serif;min-width:fit-content;">&#160;&#160;1,909</font><font style="color:#000000;white-space:pre-wrap;font-family:'Calibri',sans-serif;min-width:fit-content;"> </font></p></td>
    <td style="padding-left:0.075in;vertical-align:bottom;border-bottom:0.5pt solid;padding-right:0.075in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><font style="color:#000000;white-space:pre-wrap;font-family:'Calibri',sans-serif;min-width:fit-content;"> </font></p></td>
    <td style="padding-left:0.075in;vertical-align:bottom;border-bottom:0.5pt solid;padding-right:0.075in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><font style="color:#000000;white-space:pre-wrap;font-family:'Calibri',sans-serif;min-width:fit-content;">&#160;&#160;3,212</font><font style="color:#000000;white-space:pre-wrap;font-family:'Calibri',sans-serif;min-width:fit-content;"> </font></p></td>
   </tr>
   <tr style="height:15.1pt;white-space:pre-wrap;word-break:break-word;">
    <td style="padding-left:0.075in;vertical-align:top;padding-right:0.075in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-family:'Calibri',sans-serif;min-width:fit-content;">Net loss</font></p></td>
    <td style="padding-left:0.075in;vertical-align:bottom;padding-right:0.075in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-family:'Calibri',sans-serif;min-width:fit-content;">&#160;</font></p></td>
    <td style="padding-left:0.075in;vertical-align:bottom;border-bottom:2.25pt double;padding-right:0.075in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><font style="color:#000000;white-space:pre-wrap;font-family:'Calibri',sans-serif;min-width:fit-content;">&#160;$         (74,950)</font></p></td>
    <td style="padding-left:0.075in;vertical-align:bottom;border-bottom:2.25pt double;padding-right:0.075in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><font style="color:#000000;white-space:pre-wrap;font-family:'Calibri',sans-serif;min-width:fit-content;"> </font></p></td>
    <td style="padding-left:0.075in;vertical-align:bottom;border-bottom:2.25pt double;padding-right:0.075in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><font style="color:#000000;white-space:pre-wrap;font-family:'Calibri',sans-serif;min-width:fit-content;">&#160;$       (49,625)</font></p></td>
   </tr>
   <tr style="height:15.1pt;background-color:#cff0fc;white-space:pre-wrap;word-break:break-word;">
    <td style="padding-left:0.075in;vertical-align:top;padding-right:0.075in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-family:'Calibri',sans-serif;min-width:fit-content;">Other comprehensive income (loss):</font></p></td>
    <td style="padding-left:0.075in;vertical-align:bottom;padding-right:0.075in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-family:'Calibri',sans-serif;min-width:fit-content;">&#160;</font></p></td>
    <td style="padding-left:0.075in;vertical-align:bottom;padding-right:0.075in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-family:'Calibri',sans-serif;min-width:fit-content;">&#160;</font></p></td>
    <td style="padding-left:0.075in;vertical-align:bottom;padding-right:0.075in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><font style="white-space:pre-wrap;font-family:'Calibri',sans-serif;min-width:fit-content;">&#160;</font></p></td>
    <td style="padding-left:0.075in;vertical-align:bottom;padding-right:0.075in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><font style="white-space:pre-wrap;font-family:'Calibri',sans-serif;min-width:fit-content;">&#160;</font></p></td>
   </tr>
   <tr style="height:14.4pt;white-space:pre-wrap;word-break:break-word;">
    <td style="padding-left:0.075in;vertical-align:top;padding-right:0.075in;"><p style="text-indent:3.707%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-family:'Calibri',sans-serif;min-width:fit-content;">Unrealized gains  on available-for-sale securities</font></p></td>
    <td style="padding-left:0.075in;vertical-align:bottom;padding-right:0.075in;"><p style="text-indent:3.707%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-family:'Calibri',sans-serif;min-width:fit-content;">&#160;</font></p></td>
    <td style="padding-left:0.075in;vertical-align:bottom;padding-right:0.075in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><font style="color:#000000;white-space:pre-wrap;font-family:'Calibri',sans-serif;min-width:fit-content;">&#160;&#160;137</font><font style="color:#000000;white-space:pre-wrap;font-family:'Calibri',sans-serif;min-width:fit-content;"> </font></p></td>
    <td style="padding-left:0.075in;vertical-align:bottom;padding-right:0.075in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><font style="white-space:pre-wrap;font-family:'Calibri',sans-serif;min-width:fit-content;">&#160;</font></p></td>
    <td style="padding-left:0.075in;vertical-align:bottom;padding-right:0.075in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><font style="color:#000000;white-space:pre-wrap;font-family:'Calibri',sans-serif;min-width:fit-content;">&#160;&#160;279</font><font style="color:#000000;white-space:pre-wrap;font-family:'Calibri',sans-serif;min-width:fit-content;"> </font></p></td>
   </tr>
   <tr style="height:14.4pt;background-color:#cff0fc;white-space:pre-wrap;word-break:break-word;">
    <td style="padding-left:0.075in;vertical-align:top;padding-right:0.075in;"><p style="text-indent:3.707%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-family:'Calibri',sans-serif;min-width:fit-content;">Foreign currency translation adjustment</font></p></td>
    <td style="padding-left:0.075in;vertical-align:bottom;padding-right:0.075in;"><p style="text-indent:3.707%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-family:'Calibri',sans-serif;min-width:fit-content;">&#160;</font></p></td>
    <td style="padding-left:0.075in;vertical-align:bottom;padding-right:0.075in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><font style="color:#000000;white-space:pre-wrap;font-family:'Calibri',sans-serif;min-width:fit-content;">&#160;&#160;8</font><font style="color:#000000;white-space:pre-wrap;font-family:'Calibri',sans-serif;min-width:fit-content;"> </font></p></td>
    <td style="padding-left:0.075in;vertical-align:bottom;padding-right:0.075in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><font style="white-space:pre-wrap;font-family:'Calibri',sans-serif;min-width:fit-content;">&#160;</font></p></td>
    <td style="padding-left:0.075in;vertical-align:bottom;padding-right:0.075in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><font style="color:#000000;white-space:pre-wrap;font-family:'Calibri',sans-serif;min-width:fit-content;">&#160;&#160;(152)</font></p></td>
   </tr>
   <tr style="height:14.4pt;white-space:pre-wrap;word-break:break-word;">
    <td style="padding-left:0.075in;vertical-align:top;padding-right:0.075in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-family:'Calibri',sans-serif;min-width:fit-content;">Total other comprehensive income</font><font style="color:#000000;white-space:pre-wrap;font-family:'Calibri',sans-serif;min-width:fit-content;"> </font></p></td>
    <td style="padding-left:0.075in;vertical-align:bottom;padding-right:0.075in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-family:'Calibri',sans-serif;min-width:fit-content;">&#160;</font></p></td>
    <td style="border-top:0.5pt solid;padding-left:0.075in;vertical-align:bottom;border-bottom:0.5pt solid;padding-right:0.075in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><font style="color:#000000;white-space:pre-wrap;font-family:'Calibri',sans-serif;min-width:fit-content;">&#160;&#160;145</font><font style="color:#000000;white-space:pre-wrap;font-family:'Calibri',sans-serif;min-width:fit-content;"> </font></p></td>
    <td style="border-top:0.5pt solid;padding-left:0.075in;vertical-align:bottom;border-bottom:0.5pt solid;padding-right:0.075in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><font style="color:#000000;white-space:pre-wrap;font-family:'Calibri',sans-serif;min-width:fit-content;"> </font></p></td>
    <td style="border-top:0.5pt solid;padding-left:0.075in;vertical-align:bottom;border-bottom:0.5pt solid;padding-right:0.075in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><font style="color:#000000;white-space:pre-wrap;font-family:'Calibri',sans-serif;min-width:fit-content;">&#160;&#160;127</font><font style="color:#000000;white-space:pre-wrap;font-family:'Calibri',sans-serif;min-width:fit-content;"> </font></p></td>
   </tr>
   <tr style="height:15.1pt;background-color:#cff0fc;white-space:pre-wrap;word-break:break-word;">
    <td style="padding-left:0.075in;vertical-align:top;padding-right:0.075in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-family:'Calibri',sans-serif;min-width:fit-content;">Comprehensive loss</font></p></td>
    <td style="padding-left:0.075in;vertical-align:bottom;padding-right:0.075in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-family:'Calibri',sans-serif;min-width:fit-content;">&#160;</font></p></td>
    <td style="padding-left:0.075in;vertical-align:bottom;border-bottom:2.25pt double;padding-right:0.075in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><font style="color:#000000;white-space:pre-wrap;font-family:'Calibri',sans-serif;min-width:fit-content;">&#160;$         (74,805)</font></p></td>
    <td style="padding-left:0.075in;vertical-align:bottom;border-bottom:2.25pt double;padding-right:0.075in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><font style="color:#000000;white-space:pre-wrap;font-family:'Calibri',sans-serif;min-width:fit-content;"> </font></p></td>
    <td style="padding-left:0.075in;vertical-align:bottom;border-bottom:2.25pt double;padding-right:0.075in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><font style="color:#000000;white-space:pre-wrap;font-family:'Calibri',sans-serif;min-width:fit-content;">&#160;$       (49,498)</font></p></td>
   </tr>
   <tr style="height:27.35pt;white-space:pre-wrap;word-break:break-word;">
    <td style="padding-left:0.075in;vertical-align:top;padding-right:0.075in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-family:'Calibri',sans-serif;min-width:fit-content;">Net loss attributable to common stockholders&#x2014;basic<br>&#160;&#160;&#160;and diluted</font></p></td>
    <td style="padding-left:0.075in;vertical-align:bottom;padding-right:0.075in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-family:'Calibri',sans-serif;min-width:fit-content;">&#160;</font></p></td>
    <td style="padding-left:0.075in;vertical-align:bottom;border-bottom:2.25pt double;padding-right:0.075in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><font style="color:#000000;white-space:pre-wrap;font-family:'Calibri',sans-serif;min-width:fit-content;">&#160;$         (74,950)</font></p></td>
    <td style="padding-left:0.075in;vertical-align:bottom;border-bottom:2.25pt double;padding-right:0.075in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><font style="color:#000000;white-space:pre-wrap;font-family:'Calibri',sans-serif;min-width:fit-content;"> </font></p></td>
    <td style="padding-left:0.075in;vertical-align:bottom;border-bottom:2.25pt double;padding-right:0.075in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><font style="color:#000000;white-space:pre-wrap;font-family:'Calibri',sans-serif;min-width:fit-content;">&#160;$       (49,625)</font></p></td>
   </tr>
   <tr style="height:27.35pt;background-color:#cff0fc;white-space:pre-wrap;word-break:break-word;">
    <td style="padding-left:0.075in;vertical-align:top;padding-right:0.075in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-family:'Calibri',sans-serif;min-width:fit-content;">Net loss per share attributable to common<br>&#160;&#160;&#160;stockholders&#x2014;basic and diluted</font></p></td>
    <td style="padding-left:0.075in;vertical-align:bottom;padding-right:0.075in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-family:'Calibri',sans-serif;min-width:fit-content;">&#160;</font></p></td>
    <td style="padding-left:0.075in;vertical-align:bottom;border-bottom:2.25pt double;padding-right:0.075in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><font style="color:#000000;white-space:pre-wrap;font-family:'Calibri',sans-serif;min-width:fit-content;">&#160;$             (1.20)</font></p></td>
    <td style="padding-left:0.075in;vertical-align:bottom;border-bottom:2.25pt double;padding-right:0.075in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><font style="color:#000000;white-space:pre-wrap;font-family:'Calibri',sans-serif;min-width:fit-content;"> </font></p></td>
    <td style="padding-left:0.075in;vertical-align:bottom;border-bottom:2.25pt double;padding-right:0.075in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><font style="color:#000000;white-space:pre-wrap;font-family:'Calibri',sans-serif;min-width:fit-content;">&#160;$           (1.02)</font></p></td>
   </tr>
   <tr style="height:27.35pt;white-space:pre-wrap;word-break:break-word;">
    <td style="padding-left:0.075in;vertical-align:top;padding-right:0.075in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-family:'Calibri',sans-serif;min-width:fit-content;">Weighted-average common shares outstanding&#x2014;basic<br>&#160;&#160;&#160;and diluted</font></p></td>
    <td style="padding-left:0.075in;vertical-align:bottom;padding-right:0.075in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-family:'Calibri',sans-serif;min-width:fit-content;">&#160;</font></p></td>
    <td style="padding-left:0.075in;vertical-align:bottom;border-bottom:2.25pt double;padding-right:0.075in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><font style="color:#000000;white-space:pre-wrap;font-family:'Calibri',sans-serif;min-width:fit-content;">&#160;&#160;62,334,482</font><font style="color:#000000;white-space:pre-wrap;font-family:'Calibri',sans-serif;min-width:fit-content;"> </font></p></td>
    <td style="padding-left:0.075in;vertical-align:bottom;border-bottom:2.25pt double;padding-right:0.075in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><font style="color:#000000;white-space:pre-wrap;font-family:'Calibri',sans-serif;min-width:fit-content;"> </font></p></td>
    <td style="padding-left:0.075in;vertical-align:bottom;border-bottom:2.25pt double;padding-right:0.075in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><font style="color:#000000;white-space:pre-wrap;font-family:'Calibri',sans-serif;min-width:fit-content;">&#160;&#160;48,494,175</font><font style="color:#000000;white-space:pre-wrap;font-family:'Calibri',sans-serif;min-width:fit-content;"> </font></p></td>
   </tr>
  </table>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:8pt;text-align:center;"><font style="white-space:pre-wrap;font-size:12pt;font-family:'Calibri',sans-serif;min-width:fit-content;">&#160;</font></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:8pt;text-align:left;"><font style="white-space:pre-wrap;font-size:12pt;font-family:'Calibri',sans-serif;min-width:fit-content;">&#160;</font></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:8pt;text-align:left;"><font style="white-space:pre-wrap;font-size:12pt;font-family:'Calibri',sans-serif;min-width:fit-content;">&#160;</font></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:8pt;text-align:left;"><font style="white-space:pre-wrap;font-size:12pt;font-family:'Calibri',sans-serif;min-width:fit-content;">&#160;</font></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:8pt;text-align:left;"><font style="white-space:pre-wrap;font-size:12pt;font-family:'Calibri',sans-serif;min-width:fit-content;">&#160;</font></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:8pt;text-align:left;"><font style="white-space:pre-wrap;font-size:12pt;font-family:'Calibri',sans-serif;min-width:fit-content;">&#160;</font></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:8pt;text-align:left;"><font style="white-space:pre-wrap;font-size:12pt;font-family:'Calibri',sans-serif;min-width:fit-content;">&#160;</font></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:8pt;text-align:left;"><font style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</font></p>
  <div class="page-node-content"><div style="z-index:-3;flex-direction:column;display:flex;min-height:1in;justify-content:flex-end;position:relative;"></div></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;page-break-after:always;">
  <div style="padding-top:0.5in;z-index:-3;min-height:1in;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><img src="img4202433_0.jpg" alt="img4202433_0.jpg" style="width:180px;height:90px;"></p></div>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:8pt;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:12pt;font-family:'Calibri',sans-serif;min-width:fit-content;">Contacts</font></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:'Calibri',sans-serif;min-width:fit-content;">Investors:<br>Inozyme Pharma<br>Stefan Riley, Senior Director of IR and Corporate Communications<br>(857) 330-8871<br></font><font><font style="white-space:pre-wrap;font-weight:bold;font-size:12pt;font-family:'Calibri',sans-serif;min-width:fit-content;">Stefan.riley@inozyme.com</font></font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:'Calibri',sans-serif;min-width:fit-content;">&#160;</font></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:12pt;font-family:'Calibri',sans-serif;min-width:fit-content;">&#160;</font></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:'Calibri',sans-serif;min-width:fit-content;">Media:<br>Biongage Communications<br>Todd Cooper<br>(617) 840-1637<br></font><font><font style="white-space:pre-wrap;font-weight:bold;font-size:12pt;font-family:'Calibri',sans-serif;min-width:fit-content;">Todd@biongage.com</font></font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:'Calibri',sans-serif;min-width:fit-content;">&#160;</font></p>
  <div class="page-node-content"><div style="z-index:-3;flex-direction:column;display:flex;min-height:1in;justify-content:flex-end;position:relative;"></div></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;page-break-after:always;">
 </body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>3
<FILENAME>img4202433_0.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 img4202433_0.jpg
M_]C_X  02D9)1@ ! @   0 !  #_VP!#  @&!@<&!0@'!P<)"0@*#!0-# L+
M#!D2$P\4'1H?'AT:'!P@)"XG("(L(QP<*#<I+# Q-#0T'R<Y/3@R/"XS-#+_
MVP!# 0D)"0P+#!@-#1@R(1PA,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R
M,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C+_P  1" "? 3X# 2(  A$! Q$!_\0
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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M60-.JA?-1P=I('&[*MG&!TKT&L#PEX1T[P=I366G^9(9'\R:>4@O(V,<XP
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ML1*#PS ]01THH22FVQU5[NA>^&__ "1SQ?\ [UU_Z3)7C4O^H?\ W3_*O??
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M\1Z)'%&H1$6]B 4 8  STKP'_A6'C;_H7YO_  (A_P#BZ/\ A6'C;_H7YO\
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
:*** "BBB@ HHHH **** "BBB@ HHHH __]D!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.SCH
<SEQUENCE>4
<FILENAME>inzy-20241105.xsd
<DESCRIPTION>XBRL TAXONOMY EXTENSION SCHEMA WITH EMBEDDED LINKBASES DOCUMENT
<TEXT>
<XBRL>
<?xml version="1.0" encoding="US-ASCII"?>
<!-- DFIN New ActiveDisclosure (SM) XBRL Schema Document - http://www.dfinsolutions.com/ -->
<!-- Creation Date :2024-11-04T20:19:06.6351+00:00 -->
<!-- Copyright (c) 2024 Donnelley Financial Solutions, Inc. All Rights Reserved. -->
<xsd:schema targetNamespace="http://www.inozyme.com/20241105" attributeFormDefault="unqualified" elementFormDefault="qualified" xmlns:enum2="http://xbrl.org/2020/extensible-enumerations-2.0" xmlns:inzy="http://www.inozyme.com/20241105" xmlns:xsd="http://www.w3.org/2001/XMLSchema" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:us-gaap="http://fasb.org/us-gaap/2024" xmlns:dei="http://xbrl.sec.gov/dei/2024" xmlns:xbrldt="http://xbrl.org/2005/xbrldt" xmlns:xbrli="http://www.xbrl.org/2003/instance" xmlns:xlink="http://www.w3.org/1999/xlink">
  <xsd:import schemaLocation="http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd" namespace="http://www.xbrl.org/2003/instance"/>
  <xsd:import schemaLocation="http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd" namespace="http://www.xbrl.org/2003/linkbase"/>
  <xsd:import schemaLocation="http://www.xbrl.org/2005/xbrldt-2005.xsd" namespace="http://xbrl.org/2005/xbrldt"/>
  <xsd:import schemaLocation="https://xbrl.sec.gov/dei/2024/dei-2024.xsd" namespace="http://xbrl.sec.gov/dei/2024"/>
  <xsd:import schemaLocation="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd" namespace="http://fasb.org/us-gaap/2024"/>
  <xsd:annotation>
    <xsd:appinfo>
      <link:roleType roleURI="http://www.inozyme.com/20241105/taxonomy/role/DocumentDocumentAndEntityInformation" id="Role_DocumentDocumentAndEntityInformation">
        <link:definition>100000 - Document - Document And Entity Information</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:linkbase id="lnk">
        <link:roleRef roleURI="http://www.inozyme.com/20241105/taxonomy/role/DocumentDocumentAndEntityInformation" xlink:href="inzy-20241105.xsd#Role_DocumentDocumentAndEntityInformation" xlink:type="simple"/>
        <link:labelLink xlink:role="http://www.xbrl.org/2003/role/link" xlink:title="labelLink" xlink:type="extended">
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_CoverAbstract" xlink:label="dei_CoverAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_AmendmentFlag" xlink:label="dei_AmendmentFlag"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_CityAreaCode" xlink:label="dei_CityAreaCode"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_DocumentPeriodEndDate" xlink:label="dei_DocumentPeriodEndDate"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_DocumentType" xlink:label="dei_DocumentType"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityAddressAddressLine1" xlink:label="dei_EntityAddressAddressLine1"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityAddressAddressLine2" xlink:label="dei_EntityAddressAddressLine2"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityAddressCityOrTown" xlink:label="dei_EntityAddressCityOrTown"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityAddressPostalZipCode" xlink:label="dei_EntityAddressPostalZipCode"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityAddressStateOrProvince" xlink:label="dei_EntityAddressStateOrProvince"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityCentralIndexKey" xlink:label="dei_EntityCentralIndexKey"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityEmergingGrowthCompany" xlink:label="dei_EntityEmergingGrowthCompany"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityExTransitionPeriod" xlink:label="dei_EntityExTransitionPeriod"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityFileNumber" xlink:label="dei_EntityFileNumber"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityIncorporationStateCountryCode" xlink:label="dei_EntityIncorporationStateCountryCode"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityRegistrantName" xlink:label="dei_EntityRegistrantName"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityTaxIdentificationNumber" xlink:label="dei_EntityTaxIdentificationNumber"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_LocalPhoneNumber" xlink:label="dei_LocalPhoneNumber"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_PreCommencementIssuerTenderOffer" xlink:label="dei_PreCommencementIssuerTenderOffer"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_PreCommencementTenderOffer" xlink:label="dei_PreCommencementTenderOffer"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_Security12bTitle" xlink:label="dei_Security12bTitle"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_SecurityExchangeName" xlink:label="dei_SecurityExchangeName"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_SolicitingMaterial" xlink:label="dei_SolicitingMaterial"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_TradingSymbol" xlink:label="dei_TradingSymbol"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_WrittenCommunications" xlink:label="dei_WrittenCommunications"/>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_CoverAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Cover [Abstract]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_AmendmentFlag_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Amendment Flag</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_CityAreaCode_lbl" xlink:role="http://www.xbrl.org/2003/role/label">City Area Code</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_DocumentPeriodEndDate_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Document Period End Date</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_DocumentType_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Document Type</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_EntityAddressAddressLine1_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Entity Address, Address Line One</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_EntityAddressAddressLine2_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Entity Address, Address Line Two</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_EntityAddressCityOrTown_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Entity Address, City or Town</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_EntityAddressPostalZipCode_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Entity Address, Postal Zip Code</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_EntityAddressStateOrProvince_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Entity Address, State or Province</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_EntityCentralIndexKey_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Entity Central Index Key</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_EntityEmergingGrowthCompany_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Entity Emerging Growth Company</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_EntityExTransitionPeriod_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Entity Ex Transition Period</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_EntityFileNumber_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Entity File Number</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_EntityIncorporationStateCountryCode_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Entity Incorporation, State or Country Code</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_EntityRegistrantName_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Entity Registrant Name</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_EntityTaxIdentificationNumber_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Entity Tax Identification Number</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_LocalPhoneNumber_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Local Phone Number</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_PreCommencementIssuerTenderOffer_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Pre-commencement Issuer Tender Offer</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_PreCommencementTenderOffer_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Pre-commencement Tender Offer</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_Security12bTitle_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Title of 12(b) Security</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_SecurityExchangeName_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Security Exchange Name</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_SolicitingMaterial_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Soliciting Material</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_TradingSymbol_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Trading Symbol</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_WrittenCommunications_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Written Communications</link:label>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_CoverAbstract" xlink:to="dei_CoverAbstract_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_AmendmentFlag" xlink:to="dei_AmendmentFlag_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_CityAreaCode" xlink:to="dei_CityAreaCode_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentPeriodEndDate" xlink:to="dei_DocumentPeriodEndDate_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentType" xlink:to="dei_DocumentType_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityAddressAddressLine1" xlink:to="dei_EntityAddressAddressLine1_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityAddressAddressLine2" xlink:to="dei_EntityAddressAddressLine2_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityAddressCityOrTown" xlink:to="dei_EntityAddressCityOrTown_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityAddressPostalZipCode" xlink:to="dei_EntityAddressPostalZipCode_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityAddressStateOrProvince" xlink:to="dei_EntityAddressStateOrProvince_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityCentralIndexKey" xlink:to="dei_EntityCentralIndexKey_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityEmergingGrowthCompany" xlink:to="dei_EntityEmergingGrowthCompany_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityExTransitionPeriod" xlink:to="dei_EntityExTransitionPeriod_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityFileNumber" xlink:to="dei_EntityFileNumber_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityIncorporationStateCountryCode" xlink:to="dei_EntityIncorporationStateCountryCode_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityRegistrantName" xlink:to="dei_EntityRegistrantName_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityTaxIdentificationNumber" xlink:to="dei_EntityTaxIdentificationNumber_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_LocalPhoneNumber" xlink:to="dei_LocalPhoneNumber_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_PreCommencementIssuerTenderOffer" xlink:to="dei_PreCommencementIssuerTenderOffer_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_PreCommencementTenderOffer" xlink:to="dei_PreCommencementTenderOffer_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_Security12bTitle" xlink:to="dei_Security12bTitle_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_SecurityExchangeName" xlink:to="dei_SecurityExchangeName_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_SolicitingMaterial" xlink:to="dei_SolicitingMaterial_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_TradingSymbol" xlink:to="dei_TradingSymbol_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_WrittenCommunications" xlink:to="dei_WrittenCommunications_lbl"/>
        </link:labelLink>
        <link:presentationLink xlink:role="http://www.inozyme.com/20241105/taxonomy/role/DocumentDocumentAndEntityInformation" xlink:title="presentationLink" xlink:type="extended">
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_CoverAbstract" xlink:label="dei_CoverAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_AmendmentFlag" xlink:label="dei_AmendmentFlag"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_CityAreaCode" xlink:label="dei_CityAreaCode"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_DocumentPeriodEndDate" xlink:label="dei_DocumentPeriodEndDate"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_DocumentType" xlink:label="dei_DocumentType"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityAddressAddressLine1" xlink:label="dei_EntityAddressAddressLine1"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityAddressAddressLine2" xlink:label="dei_EntityAddressAddressLine2"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityAddressCityOrTown" xlink:label="dei_EntityAddressCityOrTown"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityAddressPostalZipCode" xlink:label="dei_EntityAddressPostalZipCode"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityAddressStateOrProvince" xlink:label="dei_EntityAddressStateOrProvince"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityCentralIndexKey" xlink:label="dei_EntityCentralIndexKey"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityEmergingGrowthCompany" xlink:label="dei_EntityEmergingGrowthCompany"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityExTransitionPeriod" xlink:label="dei_EntityExTransitionPeriod"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityFileNumber" xlink:label="dei_EntityFileNumber"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityIncorporationStateCountryCode" xlink:label="dei_EntityIncorporationStateCountryCode"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityRegistrantName" xlink:label="dei_EntityRegistrantName"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityTaxIdentificationNumber" xlink:label="dei_EntityTaxIdentificationNumber"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_LocalPhoneNumber" xlink:label="dei_LocalPhoneNumber"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_PreCommencementIssuerTenderOffer" xlink:label="dei_PreCommencementIssuerTenderOffer"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_PreCommencementTenderOffer" xlink:label="dei_PreCommencementTenderOffer"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_Security12bTitle" xlink:label="dei_Security12bTitle"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_SecurityExchangeName" xlink:label="dei_SecurityExchangeName"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_SolicitingMaterial" xlink:label="dei_SolicitingMaterial"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_TradingSymbol" xlink:label="dei_TradingSymbol"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_WrittenCommunications" xlink:label="dei_WrittenCommunications"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_AmendmentFlag" order="10010.0" priority="2" use="optional"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_CityAreaCode" order="10130.0" priority="2" use="optional"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_DocumentPeriodEndDate" order="10020.0" priority="2" use="optional"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_DocumentType" order="10000.0" priority="2" use="optional"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntityAddressAddressLine1" order="10090.0" priority="2" use="optional"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntityAddressAddressLine2" order="10091.0" priority="2" use="optional"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntityAddressCityOrTown" order="10100.0" priority="2" use="optional"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntityAddressPostalZipCode" order="10120.0" priority="2" use="optional"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntityAddressStateOrProvince" order="10110.0" priority="2" use="optional"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntityCentralIndexKey" order="10040.0" priority="2" use="optional"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntityEmergingGrowthCompany" order="10050.0" priority="2" use="optional"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntityExTransitionPeriod" order="10200.0" priority="2" use="optional"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntityFileNumber" order="10060.0" priority="2" use="optional"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntityIncorporationStateCountryCode" order="10070.0" priority="2" use="optional"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntityRegistrantName" order="10030.0" priority="2" use="optional"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntityTaxIdentificationNumber" order="10080.0" priority="2" use="optional"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_LocalPhoneNumber" order="10140.0" priority="2" use="optional"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_PreCommencementIssuerTenderOffer" order="10190.0" priority="2" use="optional"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_PreCommencementTenderOffer" order="10180.0" priority="2" use="optional"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_Security12bTitle" order="10210.0" priority="2" use="optional"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_SecurityExchangeName" order="10340.0" priority="2" use="optional"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_SolicitingMaterial" order="10170.0" priority="2" use="optional"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_TradingSymbol" order="10220.0" priority="2" use="optional"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_WrittenCommunications" order="10160.0" priority="2" use="optional"/>
        </link:presentationLink>
      </link:linkbase>
    </xsd:appinfo>
  </xsd:annotation>
</xsd:schema>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>6
<FILENAME>R1.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.3</span><table class="report" border="0" cellspacing="2" id="idm45671365398304">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Document And Entity Information<br></strong></div></th>
<th class="th"><div>Nov. 05, 2024</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_CoverAbstract', window );"><strong>Cover [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_DocumentType', window );">Document Type</a></td>
<td class="text">8-K<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_AmendmentFlag', window );">Amendment Flag</a></td>
<td class="text">false<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_DocumentPeriodEndDate', window );">Document Period End Date</a></td>
<td class="text">Nov.  05,  2024<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityRegistrantName', window );">Entity Registrant Name</a></td>
<td class="text">INOZYME PHARMA, INC.<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityCentralIndexKey', window );">Entity Central Index Key</a></td>
<td class="text">0001693011<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityEmergingGrowthCompany', window );">Entity Emerging Growth Company</a></td>
<td class="text">true<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityFileNumber', window );">Entity File Number</a></td>
<td class="text">001-39397<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityIncorporationStateCountryCode', window );">Entity Incorporation, State or Country Code</a></td>
<td class="text">DE<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityTaxIdentificationNumber', window );">Entity Tax Identification Number</a></td>
<td class="text">38-4024528<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityAddressAddressLine1', window );">Entity Address, Address Line One</a></td>
<td class="text">321 Summer Street<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityAddressAddressLine2', window );">Entity Address, Address Line Two</a></td>
<td class="text">Suite 400<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityAddressCityOrTown', window );">Entity Address, City or Town</a></td>
<td class="text">Boston<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityAddressStateOrProvince', window );">Entity Address, State or Province</a></td>
<td class="text">MA<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityAddressPostalZipCode', window );">Entity Address, Postal Zip Code</a></td>
<td class="text">02210<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_CityAreaCode', window );">City Area Code</a></td>
<td class="text">857<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_LocalPhoneNumber', window );">Local Phone Number</a></td>
<td class="text">330-4340<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_WrittenCommunications', window );">Written Communications</a></td>
<td class="text">false<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_SolicitingMaterial', window );">Soliciting Material</a></td>
<td class="text">false<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_PreCommencementTenderOffer', window );">Pre-commencement Tender Offer</a></td>
<td class="text">false<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_PreCommencementIssuerTenderOffer', window );">Pre-commencement Issuer Tender Offer</a></td>
<td class="text">false<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityExTransitionPeriod', window );">Entity Ex Transition Period</a></td>
<td class="text">false<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_Security12bTitle', window );">Title of 12(b) Security</a></td>
<td class="text">Common stock, par value $0.0001 per share<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_TradingSymbol', window );">Trading Symbol</a></td>
<td class="text">INZY<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_SecurityExchangeName', window );">Security Exchange Name</a></td>
<td class="text">NASDAQ<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_AmendmentFlag">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the XBRL content amends previously-filed or accepted submission.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_AmendmentFlag</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_CityAreaCode">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Area code of city</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_CityAreaCode</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_CoverAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Cover page.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_CoverAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentPeriodEndDate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>For the EDGAR submission types of Form 8-K: the date of the report, the date of the earliest event reported; for the EDGAR submission types of Form N-1A: the filing date; for all other submission types: the end of the reporting or transition period. The format of the date is YYYY-MM-DD.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentPeriodEndDate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:dateItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentType">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentType</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:submissionTypeItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressAddressLine1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Address Line 1 such as Attn, Building Name, Street Name</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressAddressLine1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressAddressLine2">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Address Line 2 such as Street or Suite number</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressAddressLine2</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressCityOrTown">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Name of the City or Town</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressCityOrTown</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressPostalZipCode">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Code for the postal or zip code</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressPostalZipCode</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressStateOrProvince">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Name of the state or province.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressStateOrProvince</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:stateOrProvinceItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityCentralIndexKey">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityCentralIndexKey</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:centralIndexKeyItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityEmergingGrowthCompany">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Indicate if registrant meets the emerging growth company criteria.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityEmergingGrowthCompany</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityExTransitionPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Indicate if an emerging growth company has elected not to use the extended transition period for complying with any new or revised financial accounting standards.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Securities Act<br> -Number 7A<br> -Section B<br> -Subsection 2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityExTransitionPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityFileNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityFileNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:fileNumberItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityIncorporationStateCountryCode">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Two-character EDGAR code representing the state or country of incorporation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityIncorporationStateCountryCode</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:edgarStateCountryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityRegistrantName">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityRegistrantName</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityTaxIdentificationNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityTaxIdentificationNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:employerIdItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_LocalPhoneNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Local phone number for entity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_LocalPhoneNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_PreCommencementIssuerTenderOffer">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 13e<br> -Subsection 4c<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_PreCommencementIssuerTenderOffer</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_PreCommencementTenderOffer">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 14d<br> -Subsection 2b<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_PreCommencementTenderOffer</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_Security12bTitle">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Title of a 12(b) registered security.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_Security12bTitle</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:securityTitleItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_SecurityExchangeName">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Name of the Exchange on which a security is registered.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection d1-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_SecurityExchangeName</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:edgarExchangeCodeItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_SolicitingMaterial">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as soliciting material pursuant to Rule 14a-12 under the Exchange Act.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 14a<br> -Subsection 12<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_SolicitingMaterial</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_TradingSymbol">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Trading symbol of an instrument as listed on an exchange.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_TradingSymbol</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:tradingSymbolItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_WrittenCommunications">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as written communications pursuant to Rule 425 under the Securities Act.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Securities Act<br> -Number 230<br> -Section 425<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_WrittenCommunications</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EXCEL
<SEQUENCE>7
<FILENAME>Financial_Report.xlsx
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
begin 644 Financial_Report.xlsx
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M-^2!8ECFS_A[QA?_&\[Q$<+NOS^QO-9.&G_FB^$_7G\!4$L! A0#%     @
M\$-E60=!36*!    L0   !               ( !     &1O8U!R;W!S+V%P
M<"YX;6Q02P$"% ,4    " #P0V598>0&I^X    K @  $0
M@ &O    9&]C4')O<',O8V]R92YX;6Q02P$"% ,4    " #P0V59F5R<(Q &
M  "<)P  $P              @ ', 0  >&PO=&AE;64O=&AE;64Q+GAM;%!+
M 0(4 Q0    ( /!#95ET(2UPAP0  ,P1   8              " @0T(  !X
M;"]W;W)K<VAE971S+W-H965T,2YX;6Q02P$"% ,4    " #Q0V59GZ ;\+$"
M  #B#   #0              @ '*#   >&PO<W1Y;&5S+GAM;%!+ 0(4 Q0
M   ( /%#95F7BKL<P    !,"   +              "  :8/  !?<F5L<R\N
M<F5L<U!+ 0(4 Q0    ( /%#95DZJJ+G0 $  #P"   /              "
M 8\0  !X;"]W;W)K8F]O:RYX;6Q02P$"% ,4    " #Q0V59)!Z;HJT   #X
M 0  &@              @ '\$0  >&PO7W)E;',O=V]R:V)O;VLN>&UL+G)E
M;'-02P$"% ,4    " #Q0V5999!YDAD!  #/ P  $P              @ 'A
L$@  6T-O;G1E;G1?5'EP97-=+GAM;%!+!08     "0 ) #X"   K%      !

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>8
<FILENAME>Show.js
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
// Edgar(tm) Renderer was created by staff of the U.S. Securities and Exchange Commission.  Data and content created by government employees within the scope of their employment are not subject to domestic copyright protection. 17 U.S.C. 105.
var Show={};Show.LastAR=null,Show.showAR=function(a,r,w){if(Show.LastAR)Show.hideAR();var e=a;while(e&&e.nodeName!='TABLE')e=e.nextSibling;if(!e||e.nodeName!='TABLE'){var ref=((window)?w.document:document).getElementById(r);if(ref){e=ref.cloneNode(!0);
e.removeAttribute('id');a.parentNode.appendChild(e)}}
if(e)e.style.display='block';Show.LastAR=e};Show.hideAR=function(){Show.LastAR.style.display='none'};Show.toggleNext=function(a){var e=a;while(e.nodeName!='DIV')e=e.nextSibling;if(!e.style){}else if(!e.style.display){}else{var d,p_;if(e.style.display=='none'){d='block';p='-'}else{d='none';p='+'}
e.style.display=d;if(a.textContent){a.textContent=p+a.textContent.substring(1)}else{a.innerText=p+a.innerText.substring(1)}}}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>9
<FILENAME>report.css
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
/* Updated 2009-11-04 */
/* v2.2.0.24 */

/* DefRef Styles */
..report table.authRefData{
	background-color: #def;
	border: 2px solid #2F4497;
	font-size: 1em;
	position: absolute;
}

..report table.authRefData a {
	display: block;
	font-weight: bold;
}

..report table.authRefData p {
	margin-top: 0px;
}

..report table.authRefData .hide {
	background-color: #2F4497;
	padding: 1px 3px 0px 0px;
	text-align: right;
}

..report table.authRefData .hide a:hover {
	background-color: #2F4497;
}

..report table.authRefData .body {
	height: 150px;
	overflow: auto;
	width: 400px;
}

..report table.authRefData table{
	font-size: 1em;
}

/* Report Styles */
..pl a, .pl a:visited {
	color: black;
	text-decoration: none;
}

/* table */
..report {
	background-color: white;
	border: 2px solid #acf;
	clear: both;
	color: black;
	font: normal 8pt Helvetica, Arial, san-serif;
	margin-bottom: 2em;
}

..report hr {
	border: 1px solid #acf;
}

/* Top labels */
..report th {
	background-color: #acf;
	color: black;
	font-weight: bold;
	text-align: center;
}

..report th.void	{
	background-color: transparent;
	color: #000000;
	font: bold 10pt Helvetica, Arial, san-serif;
	text-align: left;
}

..report .pl {
	text-align: left;
	vertical-align: top;
	white-space: normal;
	width: 200px;
	white-space: normal; /* word-wrap: break-word; */
}

..report td.pl a.a {
	cursor: pointer;
	display: block;
	width: 200px;
	overflow: hidden;
}

..report td.pl div.a {
	width: 200px;
}

..report td.pl a:hover {
	background-color: #ffc;
}

/* Header rows... */
..report tr.rh {
	background-color: #acf;
	color: black;
	font-weight: bold;
}

/* Calendars... */
..report .rc {
	background-color: #f0f0f0;
}

/* Even rows... */
..report .re, .report .reu {
	background-color: #def;
}

..report .reu td {
	border-bottom: 1px solid black;
}

/* Odd rows... */
..report .ro, .report .rou {
	background-color: white;
}

..report .rou td {
	border-bottom: 1px solid black;
}

..report .rou table td, .report .reu table td {
	border-bottom: 0px solid black;
}

/* styles for footnote marker */
..report .fn {
	white-space: nowrap;
}

/* styles for numeric types */
..report .num, .report .nump {
	text-align: right;
	white-space: nowrap;
}

..report .nump {
	padding-left: 2em;
}

..report .nump {
	padding: 0px 0.4em 0px 2em;
}

/* styles for text types */
..report .text {
	text-align: left;
	white-space: normal;
}

..report .text .big {
	margin-bottom: 1em;
	width: 17em;
}

..report .text .more {
	display: none;
}

..report .text .note {
	font-style: italic;
	font-weight: bold;
}

..report .text .small {
	width: 10em;
}

..report sup {
	font-style: italic;
}

..report .outerFootnotes {
	font-size: 1em;
}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>11
<FILENAME>FilingSummary.xml
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<XML>
<?xml version='1.0' encoding='utf-8'?>
<FilingSummary>
  <Version>3.24.3</Version>
  <ProcessingTime/>
  <ReportFormat>html</ReportFormat>
  <ContextCount>1</ContextCount>
  <ElementCount>24</ElementCount>
  <EntityCount>1</EntityCount>
  <FootnotesReported>false</FootnotesReported>
  <SegmentCount>0</SegmentCount>
  <ScenarioCount>0</ScenarioCount>
  <TuplesReported>false</TuplesReported>
  <UnitCount>0</UnitCount>
  <MyReports>
    <Report instance="inzy-20241105.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R1.htm</HtmlFileName>
      <LongName>100000 - Document - Document And Entity Information</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.inozyme.com/20241105/taxonomy/role/DocumentDocumentAndEntityInformation</Role>
      <ShortName>Document And Entity Information</ShortName>
      <MenuCategory>Cover</MenuCategory>
      <Position>1</Position>
    </Report>
    <Report>
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <LongName>All Reports</LongName>
      <ReportType>Book</ReportType>
      <ShortName>All Reports</ShortName>
    </Report>
  </MyReports>
  <InputFiles>
    <File doctype="8-K" isOnlyDei="true" isUsgaap="true" original="inzy-20241105.htm">inzy-20241105.htm</File>
    <File>inzy-20241105.xsd</File>
  </InputFiles>
  <SupplementalFiles/>
  <BaseTaxonomies>
    <BaseTaxonomy items="24">http://xbrl.sec.gov/dei/2024</BaseTaxonomy>
  </BaseTaxonomies>
  <HasPresentationLinkbase>false</HasPresentationLinkbase>
  <HasCalculationLinkbase>false</HasCalculationLinkbase>
</FilingSummary>
</XML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>JSON
<SEQUENCE>13
<FILENAME>MetaLinks.json
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
{
 "version": "2.2",
 "instance": {
  "inzy-20241105.htm": {
   "nsprefix": "inzy",
   "nsuri": "http://www.inozyme.com/20241105",
   "dts": {
    "inline": {
     "local": [
      "inzy-20241105.htm"
     ]
    },
    "schema": {
     "local": [
      "inzy-20241105.xsd"
     ],
     "remote": [
      "http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd",
      "http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd",
      "http://www.xbrl.org/2003/xl-2003-12-31.xsd",
      "http://www.xbrl.org/2003/xlink-2003-12-31.xsd",
      "http://www.xbrl.org/2005/xbrldt-2005.xsd",
      "http://www.xbrl.org/2006/ref-2006-02-27.xsd",
      "https://www.xbrl.org/2020/extensible-enumerations-2.0.xsd",
      "https://www.xbrl.org/dtr/type/2020-01-21/types.xsd",
      "https://www.xbrl.org/dtr/type/2022-03-31/types.xsd",
      "https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd",
      "https://xbrl.fasb.org/srt/2024/elts/srt-roles-2024.xsd",
      "https://xbrl.fasb.org/srt/2024/elts/srt-types-2024.xsd",
      "https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd",
      "https://xbrl.fasb.org/us-gaap/2024/elts/us-roles-2024.xsd",
      "https://xbrl.fasb.org/us-gaap/2024/elts/us-types-2024.xsd",
      "https://xbrl.sec.gov/country/2024/country-2024.xsd",
      "https://xbrl.sec.gov/dei/2024/dei-2024.xsd",
      "https://xbrl.sec.gov/stpr/2024/stpr-2024.xsd"
     ]
    }
   },
   "keyStandard": 24,
   "keyCustom": 0,
   "axisStandard": 0,
   "axisCustom": 0,
   "memberStandard": 0,
   "memberCustom": 0,
   "hidden": {
    "total": 2,
    "http://xbrl.sec.gov/dei/2024": 2
   },
   "contextCount": 1,
   "entityCount": 1,
   "segmentCount": 0,
   "elementCount": 25,
   "unitCount": 0,
   "baseTaxonomies": {
    "http://xbrl.sec.gov/dei/2024": 24
   },
   "report": {
    "R1": {
     "role": "http://www.inozyme.com/20241105/taxonomy/role/DocumentDocumentAndEntityInformation",
     "longName": "100000 - Document - Document And Entity Information",
     "shortName": "Document And Entity Information",
     "isDefault": "true",
     "groupType": "document",
     "subGroupType": "",
     "menuCat": "Cover",
     "order": "1",
     "firstAnchor": {
      "contextRef": "C_cb007e65-08e4-4ab7-b031-aea3e45b9ea2",
      "name": "dei:DocumentType",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "span",
       "p",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "inzy-20241105.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "C_cb007e65-08e4-4ab7-b031-aea3e45b9ea2",
      "name": "dei:DocumentType",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "span",
       "p",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "inzy-20241105.htm",
      "first": true,
      "unique": true
     }
    }
   },
   "tag": {
    "dei_AmendmentFlag": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "AmendmentFlag",
     "presentation": [
      "http://www.inozyme.com/20241105/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Amendment Flag",
        "documentation": "Boolean flag that is true when the XBRL content amends previously-filed or accepted submission."
       }
      }
     },
     "auth_ref": []
    },
    "dei_CityAreaCode": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "CityAreaCode",
     "presentation": [
      "http://www.inozyme.com/20241105/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "City Area Code",
        "documentation": "Area code of city"
       }
      }
     },
     "auth_ref": []
    },
    "dei_CoverAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "CoverAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Cover [Abstract]",
        "documentation": "Cover page."
       }
      }
     },
     "auth_ref": []
    },
    "dei_DocumentPeriodEndDate": {
     "xbrltype": "dateItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "DocumentPeriodEndDate",
     "presentation": [
      "http://www.inozyme.com/20241105/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Document Period End Date",
        "documentation": "For the EDGAR submission types of Form 8-K: the date of the report, the date of the earliest event reported; for the EDGAR submission types of Form N-1A: the filing date; for all other submission types: the end of the reporting or transition period. The format of the date is YYYY-MM-DD."
       }
      }
     },
     "auth_ref": []
    },
    "dei_DocumentType": {
     "xbrltype": "submissionTypeItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "DocumentType",
     "presentation": [
      "http://www.inozyme.com/20241105/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Document Type",
        "documentation": "The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'."
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityAddressAddressLine1": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "EntityAddressAddressLine1",
     "presentation": [
      "http://www.inozyme.com/20241105/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Address, Address Line One",
        "documentation": "Address Line 1 such as Attn, Building Name, Street Name"
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityAddressAddressLine2": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "EntityAddressAddressLine2",
     "presentation": [
      "http://www.inozyme.com/20241105/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Address, Address Line Two",
        "documentation": "Address Line 2 such as Street or Suite number"
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityAddressCityOrTown": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "EntityAddressCityOrTown",
     "presentation": [
      "http://www.inozyme.com/20241105/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Address, City or Town",
        "documentation": "Name of the City or Town"
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityAddressPostalZipCode": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "EntityAddressPostalZipCode",
     "presentation": [
      "http://www.inozyme.com/20241105/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Address, Postal Zip Code",
        "documentation": "Code for the postal or zip code"
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityAddressStateOrProvince": {
     "xbrltype": "stateOrProvinceItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "EntityAddressStateOrProvince",
     "presentation": [
      "http://www.inozyme.com/20241105/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Address, State or Province",
        "documentation": "Name of the state or province."
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityCentralIndexKey": {
     "xbrltype": "centralIndexKeyItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "EntityCentralIndexKey",
     "presentation": [
      "http://www.inozyme.com/20241105/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Central Index Key",
        "documentation": "A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK."
       }
      }
     },
     "auth_ref": [
      "r1"
     ]
    },
    "dei_EntityEmergingGrowthCompany": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "EntityEmergingGrowthCompany",
     "presentation": [
      "http://www.inozyme.com/20241105/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Emerging Growth Company",
        "documentation": "Indicate if registrant meets the emerging growth company criteria."
       }
      }
     },
     "auth_ref": [
      "r1"
     ]
    },
    "dei_EntityExTransitionPeriod": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "EntityExTransitionPeriod",
     "presentation": [
      "http://www.inozyme.com/20241105/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Ex Transition Period",
        "documentation": "Indicate if an emerging growth company has elected not to use the extended transition period for complying with any new or revised financial accounting standards."
       }
      }
     },
     "auth_ref": [
      "r7"
     ]
    },
    "dei_EntityFileNumber": {
     "xbrltype": "fileNumberItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "EntityFileNumber",
     "presentation": [
      "http://www.inozyme.com/20241105/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity File Number",
        "documentation": "Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen."
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityIncorporationStateCountryCode": {
     "xbrltype": "edgarStateCountryItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "EntityIncorporationStateCountryCode",
     "presentation": [
      "http://www.inozyme.com/20241105/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Incorporation, State or Country Code",
        "documentation": "Two-character EDGAR code representing the state or country of incorporation."
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityRegistrantName": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "EntityRegistrantName",
     "presentation": [
      "http://www.inozyme.com/20241105/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Registrant Name",
        "documentation": "The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC."
       }
      }
     },
     "auth_ref": [
      "r1"
     ]
    },
    "dei_EntityTaxIdentificationNumber": {
     "xbrltype": "employerIdItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "EntityTaxIdentificationNumber",
     "presentation": [
      "http://www.inozyme.com/20241105/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Tax Identification Number",
        "documentation": "The Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS."
       }
      }
     },
     "auth_ref": [
      "r1"
     ]
    },
    "dei_LocalPhoneNumber": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "LocalPhoneNumber",
     "presentation": [
      "http://www.inozyme.com/20241105/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Local Phone Number",
        "documentation": "Local phone number for entity."
       }
      }
     },
     "auth_ref": []
    },
    "dei_PreCommencementIssuerTenderOffer": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "PreCommencementIssuerTenderOffer",
     "presentation": [
      "http://www.inozyme.com/20241105/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Pre-commencement Issuer Tender Offer",
        "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act."
       }
      }
     },
     "auth_ref": [
      "r3"
     ]
    },
    "dei_PreCommencementTenderOffer": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "PreCommencementTenderOffer",
     "presentation": [
      "http://www.inozyme.com/20241105/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Pre-commencement Tender Offer",
        "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act."
       }
      }
     },
     "auth_ref": [
      "r5"
     ]
    },
    "dei_Security12bTitle": {
     "xbrltype": "securityTitleItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "Security12bTitle",
     "presentation": [
      "http://www.inozyme.com/20241105/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Title of 12(b) Security",
        "documentation": "Title of a 12(b) registered security."
       }
      }
     },
     "auth_ref": [
      "r0"
     ]
    },
    "dei_SecurityExchangeName": {
     "xbrltype": "edgarExchangeCodeItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "SecurityExchangeName",
     "presentation": [
      "http://www.inozyme.com/20241105/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Security Exchange Name",
        "documentation": "Name of the Exchange on which a security is registered."
       }
      }
     },
     "auth_ref": [
      "r2"
     ]
    },
    "dei_SolicitingMaterial": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "SolicitingMaterial",
     "presentation": [
      "http://www.inozyme.com/20241105/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Soliciting Material",
        "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as soliciting material pursuant to Rule 14a-12 under the Exchange Act."
       }
      }
     },
     "auth_ref": [
      "r4"
     ]
    },
    "dei_TradingSymbol": {
     "xbrltype": "tradingSymbolItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "TradingSymbol",
     "presentation": [
      "http://www.inozyme.com/20241105/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Trading Symbol",
        "documentation": "Trading symbol of an instrument as listed on an exchange."
       }
      }
     },
     "auth_ref": []
    },
    "dei_WrittenCommunications": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "WrittenCommunications",
     "presentation": [
      "http://www.inozyme.com/20241105/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Written Communications",
        "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as written communications pursuant to Rule 425 under the Securities Act."
       }
      }
     },
     "auth_ref": [
      "r6"
     ]
    }
   }
  }
 },
 "std_ref": {
  "r0": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Exchange Act",
   "Number": "240",
   "Section": "12",
   "Subsection": "b"
  },
  "r1": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Exchange Act",
   "Number": "240",
   "Section": "12",
   "Subsection": "b-2"
  },
  "r2": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Exchange Act",
   "Number": "240",
   "Section": "12",
   "Subsection": "d1-1"
  },
  "r3": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Exchange Act",
   "Number": "240",
   "Section": "13e",
   "Subsection": "4c"
  },
  "r4": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Exchange Act",
   "Number": "240",
   "Section": "14a",
   "Subsection": "12"
  },
  "r5": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Exchange Act",
   "Number": "240",
   "Section": "14d",
   "Subsection": "2b"
  },
  "r6": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Securities Act",
   "Number": "230",
   "Section": "425"
  },
  "r7": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Securities Act",
   "Number": "7A",
   "Section": "B",
   "Subsection": "2"
  }
 }
}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>ZIP
<SEQUENCE>14
<FILENAME>0000950170-24-121089-xbrl.zip
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
begin 644 0000950170-24-121089-xbrl.zip
M4$L#!!0    ( /%#95G(%RHO?!,  *^A   1    :6YZ>2TR,#(T,3$P-2YH
M=&WM/6M7X[:VW_LK=.B]+;,N2OQ^!&;.HH%I<SL#LPA=IZ=?NF1))C[CV*GM
M0-)??_:6[9! ,I"0#&$('P#;>NVM_=:6=/3/43\FUS++HS1Y^Z/>T'XD,N&I
MB)*KMS\>=]N=SH__?/?=T3\H)2?O.V?D3-Z08UY$U_(DRGF<YL-,DOWNQS>D
MD\11(LGO/UU\("<I'_9E4A!*>D4Q:#6;-S<W#1%&29[&PP+ZRAL\[3<)I57C
M[4PR?$].6"%)R] ,B^HZU:Q+0VOI?DMS&KJI6_^G:2U-FZJ6#L99=-4KR#Y_
M0[ 6])TD,H[EF+R/$I;PB,6D6_=Z ,/D#7(<Q^0"J^7D0N8RNY:B43;:*P ?
M@),D?[LW-?0;LY%F5TW=]_WF",OLE85:HR"+130IBX^JI*%I3K/\.%.TF%O4
M+HL6TT6CF0%,ES:;@,<"0)-U><#\YR\4Q\\!RR?%1_?*S\"'7^NBT6A1NSH.
M Z<<9[PNGJ3)&<Q\%O'YU421-8OQ0#:A($W*DI-1Y=&\,0$$>O/WCQ^ZO"?[
MC-X%7<@[V,\E;UREUTWXT$2"N(6DH/!MIHNZ["T@S2)C21ZF65^1(\)I4\VC
MIC[5SGS8OM2(85#-H+HS:23Y>SS32I2D?X_[4G$%CEK7-7OOW7?DJ">9@+_D
MJ(B*6+[SZ*]'S?)??-F7!5,L1N5?P^CZ[5X[30I@/'H)2-XCO'QZNU?(4=%4
M=-O$1IM5JT=!*L8D+\:Q?+O79]E5E+0(&Q;I/Z+^(,T T<7A@ F4!BWB#4:'
M""'M262=%M$/]]0@1'1=MR&B?!"S,=*!A*]'T:B%7<FL_#<20B;JWUM"(9%X
MN_?^3\^QI2<LG;J&9-1RI$X]*4-J"<<S?$-C(0/L):R/O<BH=0SR1:",>1^S
MJPK247$A0\#!GSS0-%<Z.'/2HA8+7!IHIDZ99*:T[,"7S-A[%[(XET?-F=',
M'QSGW/)TSZ26S7T8DNE3C]N<>H81A*9G6MR2TX,[36"*QFT87<;B3B+DZ%<Y
M7FV0&I"_XYN:KM\;:7,6I9D,90;"6^;OCI"%6[GB&.B-*)9N(>.]W<MA:F-D
M'_6NE^%@D!QI37:-42Z 3%3STVVJQSP=9NI)B:A6!9%"TV,AJJI*A:/Z*1+X
M'$8R(VK8<BZ?MCN_SF+D;N5W]:O9U@> L%343R! L@+US+N)FK'K>K??)L,4
M"XK67^KGNI/F#&IJ/$X0UYSBB2:PSET6^AM$'!!,BYJ'_2BIF4UKV%%R.$CS
M""4*M!<S5,+(8Y-&!G4309I!\[1(!RVC8=B#@HAT&,22?*^IG\,0QD;SZ&_9
MTK5!<5AROBI??0M9/XK'K<NH+W.E\R_2/DOJ@D%:%&D?RB* E,715=**95C@
M:/(!2^IQW/2B0E)XPV5KD$EZD['!W;Z_V!WT=1.)HM<*HX)6P@PZ^>%[W=$.
MCYK8%\ _F(5^,7!VP[4?ZG(QA!PZE]E=&'D:IUFK1NQBB&_*>0S26$RCP%L1
M!;^==2Y/3TCW\OCRM'L49,UWW=/V;Q>=R\YIEQR?G9#3W]N_')_]?$K:YQ\_
M=KK=SOF9*E9C;8TP&"O"\*_C[B^=LY\OS\\.R$FCW0#[S;;\1=-:S0S26<O2
M_G=M-%PQ2_VL2(2 F1J)";M4592AJ?I^873_<(<OA.K?GU]\)/,H>(FV]^:K
M>-N6KAD: 37T /2\8YFHNSCE@?0L7W>,P')7TN!39D'M%BGC;"L0JLS)BISN
M6A<[-EPS&_I;QH6KRFW0,Q>G9Y?DXO33^<7EIO'@0.EMQ<2G898/P4DB14JZ
MDJL AFZ2-".ZO2_>D#0D14_BIV$&AANT>3KB/99<20RBX&?=-ZT[&"P8FFJS
MIAS"@DX8$ 5^I>!CI<,"1C.2XK <F:YI#>")J@(@)&:#7+9R.6 9F*FEKP:M
M9W73UU$>!5$,9G*K+ET5@E)BPD1UX]CT"/&%XZA0 ',T.E0N)=0!K_=N%Y7Q
MJ@A@[J3<P&AID$GVN:5^4WPQAZ_OCJIR2DLYT]!TL(VO959$G,551?B"1/((
M<EQ.3LT((>C:\#U'G_J!D6R$6A>1H(J7 2%=2'38R7[]+!DX(3(OB+S&0%RF
M/DOQIC6C/Q?XXLQE8>!J- P\#]S=T*"^$3#*7(/KIN=[H/76I0L_*:_IM/2E
M]D@9- &/=%2T!+RA?>BEA]6H8&,Z!K"H3#:(S[/T6O8#<$,U^T %%!_6CT#Y
M8H8%X"]RZ:J*<UD?Y16HSF_;+5VW77#;E6&M9@T+9AC2T72JN[I++=<)J.?J
M-K5\-[2MT#%U6SQ5 I1!L@MY%>48+RW.X,M:U?J#P"^:R,[9^1___GA*/OUR
M?/'Q^(!TSMJ-)<WDQ;-M;I<5Z#8>)+\%6-H_'3$P8G!"2P543R1A.>D.),>(
MG"!10CI%3MH]!OHG>_-TOV)9,WHG'K=8/&ZCL6L\:.O.,9"7K[)2-][R=:P'
MQ_9U3'? .T[]VSUS[_G-^(52=;X^M'3+-:P C% M (N82T8]X4MJ^[JP="?0
M[,!<CS[L)#S-P%97*X?= HBYG0Z3(ANW4S%K'^-J)JY7%'*0I=?8SD8-XQ,9
MLQN6R27LX>WPV):<:NDS:84!IU*SP>!QN$D])C28:L\T?<O5F;4FT^=]%$OH
M&YR-#4Z;!D:<Z9N^^ZW/F^6;AFY:%M4M+JAEZ)(RDSE4=VR#<\$LS_'6,V^7
M;-2I5ARY8M.-3Z(),@=<4=OP5O!&YTAU=UN%>FF-KI]D-C$I^THZ8[#OO.C)
MC/S_,(MR$:DHH%IJ Z-X1IJ_V22OO2C,M=-^/\HQYXR@$"0E ^WP4^.G<]$E
MI_U!G(YEIDAI5MZ0L[0Q%UGS6/X;B;L^. %SX7RT+_)2=-\.VAVT.VB7LW9V
M/JPRD'WP6AU7&-3T@I!:(3@&S+5<JFF>XX#2"AS+6H^!?"Q$)O.\^O,A2J2^
M2>/8T$EWV =02;?(I"P>82,_]UQXANL*RQ34X;8!>/4X#2SX9=FNKAG2Y2)8
MDY-Y?RZ,#<Y%=PBUB:5IRWJ;$\8RMIFQME=FK4-&S8D+/S>?<'#C-=_2J6$Z
M0/-ZZ(!3;UI4ZH8+8LSQ!'_R2O0,G[3AW_/L,KW99"CMIS0OP$?\,HMLJO.#
M1R0 F+H?!*8FJ,:82:W X93IKDEMFTOA6_#-Y6M%NW*ES[-/67H=J<T=SQ?G
M_,CRG/'>,)=%D;_DH-FCUW8V;5J6@]M&\1(&(&!8&%+!A4<M%^RBP-9\:N@>
M<SP9^MS7UTKGGX#S6?Q'-%#1_ U&?0U#7T8'[V*%&X[H5/./"^6?,A!QT8#%
MY'0D^1"W<9#S,(RXS#<: 7L9-M&KC/>!0" H$;X8U)N;5;;+"=@EP&H-W;!?
M;P;L;>+1#]][ANX>YN12QG+02Y-Z94%M^XZ'B#%R#&A6S-8B^P];PEQC6BBE
MH+[4P3WG3%"&-C'W+%?GKA?H>OA4"P%]#AS5AFT"SWYH#7C)GA=U].81'H;P
M=>[8'J>V;SO@84A)?<WUJ&[;NA&XFBT,^ZEX_9 ",WQ",MC\ JVI4<NT5C&Y
M=F+]Y8GU;T64?^U U]>B]2U+E'V?9AB=/E.9LAFI'BN7X(!$(6;')E=2D"Y&
M/\@'EA?5AHYUY,LVS-V.@J=CY<X^M'DP/I; G@9QNR?Y9[6OC T&63K((DQ#
M 8E% AFG-TA.^!&IC'CT5Q*"+ 2[)\I)A$T((+,B)7G4'\8%2V0ZS.,QR5D1
MY>%8U:PJI $ 6N8;5/O8LML4[R&TDQ&6C.MO(8C:] ;K890NPMR.O/646.;3
MD$3N4,34 0MJ$O&,A:1H4<-2;%W+8,5.U;L[*>=+JM89_M!E__#>BX6;-AX$
M>L&F#6GX(F2&1PW'<*EE!3YE.MBJPH>W9NAQ0/A3;:I_95$!*,8$GF%2I:/D
M]\.U09K& 0.**( NGP+H#]_[KF4=/F17/1>95>@ I$[C@PRF]H5>#,'JL0R[
M8ID[^T%Q&^B^[I+V^PMBF%H#"MZ*_#FG@ZQ O,Z+(%X[]+U0<S5J, X. >,V
M]3A0L!>8/-1#[ACZDQV"+F@P#GA/KCZ"R 2Y&;]>RKW%!>E7R+A/MKK%J&Y,
M4>[,]N4)W5I@MJJ2KY-T/<WGGB,9-6TWP-6R@'J^"*@C0LMDENMSFSV5=#]E
M$F4N'L6D3I! /9Z=AR%XM:^6A $GE$\AY4$IK%N"&OO!F\<1=%GV=9*T+1TC
M, V?"M.2U K-D :,^]3!%7</*-60P9I)NI/G0YGM"'LEPC9ADO $S,<0=E7V
M/F&O_>@._RL<W;&R_KNUP4JW1F;@& WF'>BA1$;EY@ V6R\@KF6NL$]PA2V,
MNOU5NK$>[&8SF51++4/>C9D8DYC)\V8^;"+<K?8D7.(II.51([Q'>,SR?#T+
MNHLQ2;X/U8]FOIKDF==&6I<90XR41QJ.^U!V?UUI$3NZ>L5TI0CJK#JK0DDL
M65M(H..A;7AS:PA\O6S=EYZA:SEF ,Z"3D-'.'ANLT;]4'!JV-PWG<"6@>D_
M.6Y3VFICW0B4TEF>3!;&TL&P3K&AE'\^(&!YD6L6#R7Y'Y@#3=/) ,\C[KWP
M7>];)7.VD(1]9KC< +?(T32;6A;S:&"&%O69=#S)'--WC:>2<*762HVV/OKM
MG/WQ[QUI?L.D:7"+25NC#K<XM71/4"\$.<N9X9M:"(3V]#A,+5WKB($ZA^M>
M[ 6UY:JY]PO/VF.Y8'^1G^,TP$LZ9 P>-_G(LL^/VL/UQ.2"AP_]7(YLOTYH
MJ),(# -)$HP)5PO!,,S/8+](=0;!G57:*"<P0 FXN\) _U66WA0]C"8-<.66
MY43(,$K*0[K*=2K-GG-HZ>U9I2;91XYS#S'5SO0/U9)570=Z PH:X"E?F.90
M1J;P1.5'GH-ZMVT,5MU6GVJ]L3WKRIL]]O?YZ.QT <T\</@V=K?H2,'0M$S;
M<JCFV#JU;"V@H%P9Q>U$@6?;FFD]>76ZW&M1C_UG-?1V.?)-1Y.=!Z/)WS;!
M=,(OB)H#$#!SY59T+[&D!U))*0*02DFJ K'#7*I2 &:5OH+7ZZB+,$AYZ0;.
MK>HK'F/G-Q%TC=2:P+#A2R:OHQSJA9,+H1CG>*H6%L;KA 3+1%XFKHA%46!S
MGTVBP-/2J_$$GM"89INF9U&-2P_4NS!H('E )?>9I1NV'HIU\<3H<H*T\LC=
MYU]>V=#QAK-1C?D7H&Q3LAJN)ZKH*=JI5Y(FJ9!U'1C7_*MAPEB.J(BRDCIQ
M06#83P[KZY?PZ_W;8_XSS(LH'-=MJU(4..H+U\K<+@[U)C&/"M_E=5=479C3
MPCNC#F<_0,/E:P54&?Q@(:CO%HMOV#BO0O=KOOKF"_;>@W<D;"K=;\TK5YU"
M]HG1T R\NVX8%VI3V3D(PFIU$,39U-5W[10D+WYH;)KOMD(-G>/A2-4)WM4!
MWKCY0UVN1C[U&$B\Z@[ ?13D:&H:VF%E(Z@G_? -H# !]<#1, ;TWJJ-K$(X
MJANL_M=0'6I+2K74E6"=JIY-K>RZ02XQ-7(8QT1=DU6ICX':"@B$+!FHM@@7
MOI4)SO'JPE+=*!6F<CRKH:AU8+"! XE**QQF293WH!I#6[H7!5%!?+^AH\I2
MMG)[F&58I3H7'D_:JA-"D4!4-FA]-ADT \X#-(S:>7+EU^L@&+*"1?\"P40Z
MC)+)E81(;8I,)L($3;1ZB]0,0;&B8+Q7D4B1'F \%.@9;;- @@,)E"EJ/@JC
M6(J*BQ23@"4%@ELJ$36QI+Q'^H,'2-RL7S+7-+M.%ZYY]@ -O12=X!NP]4@^
M#/Z#T03%#I+$$5-+YU$YE*+'"I*7XSD 4+(*J&@:IAG^F&8,1!Y:EU6>=)\)
M9=9B/Y4@69SK6;G1TZ"ID=^U*@]P>0+D"9:3(R4P,$M;%HA6$ W07UX>L<UG
M!Y8/.=B^U=A68.%O2TWZ#4V?O@<63Y% 25IJR8K.\]<AZ?!"FAKBNSDLWR;$
MES/[$F0EU4#JW:I/%&JH:Y\;(<^W$V]Z(Y&RU]>7PC23IZC:?E)2D]O0'C[+
M?$["4<-?(1O*UQJ^^V"]+5@3?L1>K;JAR9;M.WNTMWJ%?V&$LF3GS61"/!:)
MS[ \]@24D>=%UDNGN!.9\RP:J/.=MS,_9$>C.TR\%DSLV&T=J$47_VL=C+KF
MH>N:M>.0;T=6,-++<(4K2OX>4SGR_3_U1J_H+\91&,['D6I;2%[=NM!2L1A<
MDOC2?IL\)Q>S\=@[$9WT?F!Y@G/VXGBG#:!DY!.[DJ2#5A+CZABZ$U:P\D:&
M?8148. -O6,5+<2BB$;R^T\7'XBH[N_<'5FV6\/[:FMXRQ!(=<#'UNX_Z_Q\
M=GSYV\5I=[.1I_MH>+YXW/1UV67:QU]#(/\R(/O8-8$Y^2)B&(\)9T/,\5"K
M&N5MQ]A-($D.0,,'7/0H</VLQ^*PENY*-U0%<.U #A.HI-H#NN^E&< K[H:'
MMW'#G[/"KCIKA3HK5'EP:%M@R;^F-.<=K*\95JNQW 7$9?G-6:)?O&MY?5=;
M[03##M8=K"\-UA=C&2PK53?IVX,3+UO;K%(V"?S"&,TKP\-/XU4/7_S*BX=3
M>\Y?'I:;>9.<I,.K&)S0XP:YS"1/7[0<VT8EL(-U!^M2L#;<Y4ZI6E>$;/$V
MU[YLW9<3DS-T6J3=BV1X[SJ8;!=:?^VA]:-FD(KQN^^.FKVB'[_[+U!+ P04
M    " #Q0V59\F1#1;D(  #99   $0   &EN>GDM,C R-#$Q,#4N>'-D[5Q=
M<^(V&[WOKU#IS>ZTQC;9;!MF28<FN^\PW=UD0G;:::>S8VQ!-#42KVPGT%]?
M2;;\*1L"L0V4W,38CX[.L;X/$N]^7LY=\ BIAP@>=,RNT0$0V\1!>#;H?!EK
MP_'5:-3Y^?*;=]]J&KC^,/H,/L,G,+1]] BOD6>[Q LH!*_&GUZ#WW^Y^PC&
M]@.<6^":V,$<8A]HX,'W%WU=?WIZZCI3A#WB!C[+SNO:9*X#38O KRBT^'UP
M;?D0]'M&[XUFFIKQYKYG],V+OO&V^_;LW/S>,/J&D4I&%BN*9@\^>&6_!CP5
MRQMCZ+IP!3X@;&$;62X8RUQ_ "-L=\'0=<$=3^:!.^A!^@B=;@BZ])R^%XKP
M+3J#_F=K#KV%9<-!)R4%8?+/:@Z%")ZK:1KG'6#Y/D63P(<?")U?PZD5N/Z@
M$^#_!Y:+I@@Z[/VZD+^83$#J,2L0[/4A#N:].+_EA+I=0F<\(T.'2Q]B#TU<
MJ/$P2,5K\[0>+[TP.<+_K#9@&P8SP9G8I[,H+\/4?__T,2Q0&>PB_'<F.L7-
M.-/YXXGE01D>>-K,LA9QBJGE341T]$"0D<$.1%G)'K2[,_*HLP>90/[0\56O
MQSC7PX?I4%1!F-5'GU61F/"R(#!Z'>;%Q84NGG8NOP% 5!,T7Q#J@["V?"2V
M*(B*S/@G3>:H\5N:V=/.S"X#ZP"LK&<E=/7=2,ARVHI$7,C;DI"%Q',_+\M7
M6:H;Y>B5U1]^H?&+RCP+M>YYF2JKN Y=WY-W*BFH6TA"P<*8^")??DO>7"P0
MGI+P#KO'2ZA/B0OO5PL(^,67N]':#D'WK27!9+[2>0I==N'R_Q [[[&/_-6(
M947G@D,'(-9YW+'PKQN%2X:2HP/9B("$&M/@?VR\2 T=\24# R$:2,&]T_,@
M.?C @\X-OA37"\KZ>1R^NH_L1I0X"JE(:%NN';C/3Y?0*DT6W90EE2T_V<S$
M*W:C?B=?P'=P6F_YBBZO_T#A=-#APXHFT7@%_F[SDH^ ?"9ST/%80W*C_B,C
MV9I E[^M*)KSK.B(A S1)4MTY/,$,4PV5S%P.FR03;*-,R9V)M3E;9O0K/S-
M^Y;OV(>O5X1-K(83SZ>6[4LD06W0*3[7FR$U9 7DB/F':\T4I++/&R)UQ>K*
MD$W_KH@#52\J_;@A2K(NWT**"*O.#I^5*KBIXQHFR?N."F[B<4.4PH8_=!S6
MVWK1/]82H:G@5Q[;,MG>,\CV6B'+F\0-O2=/>!W55&0;1&\)F["Z?Z!%2=NN
M"&Z#[IC-#^ -O:7D$86K@DK"^?!&*5^QIDTM=\2&M.6O<%7*-1_7*,GW;'TZ
M0WCV/TJ>_(<K,E]8N)RJ.KI9PLM[:K'E-9^TA)UZ.=MB:*-4/R 7?@[F$TA+
M*:9"&J4VPC:A;*TDYGZBE5R1@%7#564W4)VJ40%W<(;XS P+^Z>4<2ZL48KW
MUG+DL+:-IBA<B*ZI"V7Q#9'FRV7W]H'@\CI;"&F(VBUE%6W.IDJVL.9&GA=
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M2J9K+MY$%,#3ZX0E]A4;ZQ4ZS:W726&]UIWRK8CDV\A\#:N? _@7P-P*#%,
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M< '@[31"#@"13!7\[</']Q]>OX7]1&YO-/ UB,;<J9C@Q"PA4F[<U/;%898
MW,;?"O;!,_7YR7I))\1\+&J1"D2^W$<+@JH4?T&R+9")( C;!_;+IM&2>E@,
MT5@K'<%@6!.[<;0RQDFRI)2LW"7IVL<HD\'B%]"P^9BF1,*[QD=@Y_1Y>,5G
MVH6;W"'<9!V+.-AP5]AP"9;]4(8RG?4G,H ]N!D@\1@ 8@-:0H8A>>ZL/\\(
M?Y# $4\S$+0W"7XZX*V!X 1[?44)'.]($[][^1G6%#?06354\-/Z#;+<67$'
M9<4M;Q%GS3EK;B-;:T7V?A27$NCW"=X"4G[(ACG$W;&D(_R\;)QQ= GC.-&M
M#&@Z$1,1D79)S#1@D:0?X@-KG-577+,8)Z@G)J@(4?(O8%@ V/ZBLB0RL4I%
M@)+VMFT!WET@G(,I#?/4 /_9AQ\%][-4#,PXQ>.JIKN/>>?F_7F63L@X',XH
M%B-)[6&$Q* B1!V)]5* ]80,47+;&Y.MX"<8=2CH""J<S0TV>H;L0G$-=H%A
MS-5 ML).-4<#8"T*D"<Y(Q+ZF0J4HW@<I,U13A$?8D\7S%G!V4 OGB61H0K&
M]YAD_U?105D7=.O=[JD+'#D,P/"R?#3HT()#"YOQ_=ICZ,]KXG@_+$;O1D'M
M$X6F_$L&D9BQ5T9LL>/7G_[UZBG[ T7@6*&(^TU,%6BN<*;E/*AC5RY- !GO
M_515RO_+HTAED2^"NRGVT6@]C6@O!0+4#JF*/FDAXK"-46_'JV>\<9=B,9!A
MT0>=<RR"ORL1AB"Y0@S"M(H7?:ERA,<9:8C.9C]!K@TP[EA/.8MGB8HG2L<3
M##T^_O!!/F4A1E@17%@*8 =&1]Q9\#9[JZX8O)*_@;$"0/\+X[LEW6Z"M4R4
MP6@QO@/1+H47X#!#.1*U=((A"0+C(!:<T00ZH'./V3GBOX1>YC[JJ4J&,I"I
M<;9,\5H>.JCJ[!62[ I=X"-!'IH W?SX]LHY#W3S3L23!!9X/)OCD<KA3BN!
M_A3BXINC)[<A57>];>0WV7:'2)%/P.6OI!CC2=9YG7U:>ST@-S'7W@U85!RK
MMQ;X\KT%G6;!;/7:@KVAX(#\=POD51*CQG8!' [$;V9/O5 \H7C:5W1JJQ+-
MSN,8H'BZX#)P"/S!"'SK-"(P-U\S GR)O&"_\2211M$ "EU=Z#K[/:G;ISQV
M-5',SY)$$-:EX%JZO?1R(L4(20Z CT+XWZ-V$R8*XO6U\#,"V?\//F,8#811
MO"FBQ#]"T&=C$<VN;>QS<1L!+V%X)IQ6YV W7U-U24M-@<.Y)S?OV7CIP'0D
M2&U=M*N7'6049!@,X=3D'JC);<BT\P@80<9DVOPN0Z%3%8GO+[+5@0('"C9S
M#OCU$+'[,5BS\7UPUVFC7?[3W1![J3T)]GE)9U\I7ME*5!@6X,3F@EA*!+$^
M^\-P5K[T57;8.&9TS'BO:&YRMEB/*/*4Y</6*A_>FNZ&J2Q%E$MM_ &MXI75
M%,"&SJ,&UF? <7SK^/9!-[1".BI;O8Y9XN'F<OJF$A,[IG1,N2VF3%<2/968
M\FX*?B%]TWTL]F:U3/;&G;GG?J:;NWSA+E^XRQ?.NM^@>VSI H7#  X#?+-!
ME:OZ(I_'?;([WI2*SWM@+K[Z39<:]P%(.$>P4Q55417K X>=GG!ZXJ%ZXBOI
M?Q?4PMK@IP?K!*<2OM/CX+NDQ__N#H>_)P; M+WL@_4/D'B8K_^OF0S@1['S
MZV@/R"U,@=G_:+:;]2Z##D.:W0WYANOL!86NPR,8#60C?4PLZG("DCQZ0IM'
M-YGT^ J&R43$AZ%8Z#3/@4S=C$)U!:(=.DO$U#H);\V'?&/VS^\IPL>A?(?R
M'^K-M]FX<$N_*MTZ.?[X(Y_&@U=/V>OK6$1:Z)V+23LBB@7$ >5"\*Q^5LC
M/+GPU],*4U[DQ%RY 4%:;Z^T$2=2)36,1F2P?Z0*7%2ADSE.YGPS._TJ3";
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M#8$ER57./;KN/MR=O"4#6]QJH:!%WB$I+"O33)\#IH9I?HMXBI/'7R*Z\8S
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M/RC"+UQYZ'JG)SVO?792B7U7@7"2/8CEK;A#Z;L&"XY.CDZ.3E6Y +];;7'
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M,A*J5$3UM..=G;@BJGNK=AU]5]GZN'/F=5LG]S:"C3)T1O C&<%@ D-3$S"
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M/7\V2:?AS_\+4$L! A0#%     @ \4-E6<@7*B]\$P  KZ$  !$
M     ( !     &EN>GDM,C R-#$Q,#4N:'1M4$L! A0#%     @ \4-E6?)D
M0T6Y"   V60  !$              ( !JQ,  &EN>GDM,C R-#$Q,#4N>'-D
M4$L! A0#%     @ \4-E6978O0@_*0  Q$0"  \              ( !DQP
F &EN>GDM97@Y.5\Q+FAT;5!+!08      P # +L   #_10     !

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>15
<FILENAME>inzy-20241105_htm.xml
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<XML>
<?xml version="1.0" encoding="utf-8"?>
<xbrl
  xmlns="http://www.xbrl.org/2003/instance"
  xmlns:dei="http://xbrl.sec.gov/dei/2024"
  xmlns:link="http://www.xbrl.org/2003/linkbase"
  xmlns:xlink="http://www.w3.org/1999/xlink">
    <link:schemaRef xlink:href="inzy-20241105.xsd" xlink:type="simple"/>
    <context id="C_cb007e65-08e4-4ab7-b031-aea3e45b9ea2">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001693011</identifier>
        </entity>
        <period>
            <startDate>2024-11-05</startDate>
            <endDate>2024-11-05</endDate>
        </period>
    </context>
    <dei:AmendmentFlag
      contextRef="C_cb007e65-08e4-4ab7-b031-aea3e45b9ea2"
      id="F_865e8d41-72ea-46e1-8eef-4d682920afa6">false</dei:AmendmentFlag>
    <dei:EntityCentralIndexKey
      contextRef="C_cb007e65-08e4-4ab7-b031-aea3e45b9ea2"
      id="F_ccc48183-45c9-4d39-8c5c-822bf3834c4e">0001693011</dei:EntityCentralIndexKey>
    <dei:DocumentType
      contextRef="C_cb007e65-08e4-4ab7-b031-aea3e45b9ea2"
      id="F_55e73f2b-21b3-4643-b03c-cbe849162b47">8-K</dei:DocumentType>
    <dei:DocumentPeriodEndDate
      contextRef="C_cb007e65-08e4-4ab7-b031-aea3e45b9ea2"
      id="F_8a7afb70-fb88-4df2-92ba-a72c1389807e">2024-11-05</dei:DocumentPeriodEndDate>
    <dei:EntityRegistrantName
      contextRef="C_cb007e65-08e4-4ab7-b031-aea3e45b9ea2"
      id="F_da22e601-1717-476b-8715-497f54f6315d">INOZYME PHARMA, INC.</dei:EntityRegistrantName>
    <dei:EntityIncorporationStateCountryCode
      contextRef="C_cb007e65-08e4-4ab7-b031-aea3e45b9ea2"
      id="F_414724be-d0b8-4cea-8d9e-591d416b05b3">DE</dei:EntityIncorporationStateCountryCode>
    <dei:EntityFileNumber
      contextRef="C_cb007e65-08e4-4ab7-b031-aea3e45b9ea2"
      id="F_e9ae4fbc-e055-46c3-8ad0-598339471a4d">001-39397</dei:EntityFileNumber>
    <dei:EntityTaxIdentificationNumber
      contextRef="C_cb007e65-08e4-4ab7-b031-aea3e45b9ea2"
      id="F_49321344-14cd-421e-a3a6-1652ccda4868">38-4024528</dei:EntityTaxIdentificationNumber>
    <dei:EntityAddressAddressLine1
      contextRef="C_cb007e65-08e4-4ab7-b031-aea3e45b9ea2"
      id="F_9cea67d2-38bf-4f01-a747-00866000b644">321 Summer Street</dei:EntityAddressAddressLine1>
    <dei:EntityAddressAddressLine2
      contextRef="C_cb007e65-08e4-4ab7-b031-aea3e45b9ea2"
      id="F_8277d43d-6c52-4a8c-b48c-457102e7cdbd">Suite 400</dei:EntityAddressAddressLine2>
    <dei:EntityAddressCityOrTown
      contextRef="C_cb007e65-08e4-4ab7-b031-aea3e45b9ea2"
      id="F_c21e0941-2364-41f6-a334-e12738b68dce">Boston</dei:EntityAddressCityOrTown>
    <dei:EntityAddressStateOrProvince
      contextRef="C_cb007e65-08e4-4ab7-b031-aea3e45b9ea2"
      id="F_319bb30d-0aa3-4b6c-a173-55ced94bb37c">MA</dei:EntityAddressStateOrProvince>
    <dei:EntityAddressPostalZipCode
      contextRef="C_cb007e65-08e4-4ab7-b031-aea3e45b9ea2"
      id="F_fbc21aff-dcd8-47bf-b509-218a68ef9c91">02210</dei:EntityAddressPostalZipCode>
    <dei:CityAreaCode
      contextRef="C_cb007e65-08e4-4ab7-b031-aea3e45b9ea2"
      id="F_c0a0feed-9e1c-4cad-aaa3-c8471c78b11f">857</dei:CityAreaCode>
    <dei:LocalPhoneNumber
      contextRef="C_cb007e65-08e4-4ab7-b031-aea3e45b9ea2"
      id="F_d91c658c-5956-4bee-9078-15512b705d25">330-4340</dei:LocalPhoneNumber>
    <dei:WrittenCommunications
      contextRef="C_cb007e65-08e4-4ab7-b031-aea3e45b9ea2"
      id="F_e29dfa28-2627-44b9-a1a3-d9fa23f8c000">false</dei:WrittenCommunications>
    <dei:SolicitingMaterial
      contextRef="C_cb007e65-08e4-4ab7-b031-aea3e45b9ea2"
      id="F_5f98f070-2ac6-4ac5-8cb9-8b3cf1fc6215">false</dei:SolicitingMaterial>
    <dei:PreCommencementTenderOffer
      contextRef="C_cb007e65-08e4-4ab7-b031-aea3e45b9ea2"
      id="F_809c86ea-357b-4b6b-89db-6df43a479c5a">false</dei:PreCommencementTenderOffer>
    <dei:PreCommencementIssuerTenderOffer
      contextRef="C_cb007e65-08e4-4ab7-b031-aea3e45b9ea2"
      id="F_5e62b329-d34e-4f3f-bac9-668dc8b032eb">false</dei:PreCommencementIssuerTenderOffer>
    <dei:Security12bTitle
      contextRef="C_cb007e65-08e4-4ab7-b031-aea3e45b9ea2"
      id="F_463be621-f6d6-46e0-9fdc-25c936b5eb39">Common stock, par value $0.0001 per share</dei:Security12bTitle>
    <dei:TradingSymbol
      contextRef="C_cb007e65-08e4-4ab7-b031-aea3e45b9ea2"
      id="F_9a27c23e-6005-44a8-b3f4-9ae68ea63972">INZY</dei:TradingSymbol>
    <dei:SecurityExchangeName
      contextRef="C_cb007e65-08e4-4ab7-b031-aea3e45b9ea2"
      id="F_92c4ae50-6c4c-418d-8fd6-ca2930f45beb">NASDAQ</dei:SecurityExchangeName>
    <dei:EntityEmergingGrowthCompany
      contextRef="C_cb007e65-08e4-4ab7-b031-aea3e45b9ea2"
      id="F_df343546-0651-450b-8eaa-94bbb8550340">true</dei:EntityEmergingGrowthCompany>
    <dei:EntityExTransitionPeriod
      contextRef="C_cb007e65-08e4-4ab7-b031-aea3e45b9ea2"
      id="F_0a053384-0ce8-41d2-becb-ec9a41251fd0">false</dei:EntityExTransitionPeriod>
</xbrl>
</XML>
</TEXT>
</DOCUMENT>
</SEC-DOCUMENT>
